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Alternative pre-mRNA splicing adjusts the transcriptional output of the genome by generating 
related mRNAs from a single primary transcript, thereby expanding protein diversity. A 
fundamental unanswered question is how splicing factors achieve specificity in the selection of 
target substrates despite the recognition of information-poor sequence motifs. The CUGBP2 
splicing regulator plays a key role in the brain region-specific silencing of the NI exon of the 
NMDA R1 receptor. However, the sequence motifs utilized by this factor for specific target exon 
selection and the mechanism of splicing silencing are not understood. Here, I use chemical 
modification footprinting to map the contact sites of CUGBP2 to GU-rich motifs closely 
positioned at the boundaries of the branch sites of the NI exon, and demonstrate a mechanistic 
role for this specific arrangement of motifs for the regulation of branchpoint formation. General 
support for a branch site-perimeter-binding model is indicated by the identification of a group of 
novel target exons with a similar configuration of motifs that are silenced by CUGBP2. These 
results reveal an autoregulatory role for CUGBP2 as indicated by its direct interaction with 
functionally significant RNA motifs surrounding the branch sites upstream of exon 6 of the 
CUGBP2 transcript, itself. The perimeter-binding model explains how CUGBP2 can effectively 
embrace the branch site region to achieve the specificity needed for the selection of exon 
targets and the fine-tuning of alternative splicing patterns. 
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1.0  INTRODUCTION 
Maturation of many eukaryotic pre-mRNAs involves the removal of intervening intron sequences 
and the splicing of exon sequences to generate a mature mRNA transcript.  The process of 
splicing involves a two-step chemical mechanism and step-wise assembly of the spliceosome, 
the macromolecular machinery that catalyzes the splicing reaction. Splicing is a precisely 
controlled process but requires a great amount of inherent flexibility. An individual exon can be 
included or skipped in the mature mRNA by the process of alternative splicing. The strength of 
individual splice sites as well as the effects of trans-acting factors interacting with cis-regulatory 
RNA elements adjust spliceosome assembly to fine-tune splicing. Splicing factors shape 
alternative splicing patterns to adjust modular protein properties in a tissue- and developmental-
specific manner. In this way, alternative splicing greatly expands protein diversity given a fixed 
number of genes. Splicing patterns are sensitive to environmental cues and in the nervous 
system respond to extracellular stimuli such as cell depolarization. Although alternative splicing 
is fundamental to diverse cellular processes such as cell differentiation, development, gene 
expression, and maintenance of cellular homeostasis, we are only just beginning to understand 
the mechanisms of regulation.  
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1.1 PRE-MRNA SPLICING: CIS-RNA ELEMENTS AND CHEMICAL MECHANISM 
Three RNA elements are integral to the two-step chemical mechanism of splicing. These 
include the 5´ splice site, the 3´ splice site, and the branch site (Figure 1). These RNA elements 
are recognized by the splicing machinery to define the exon to be spliced and to guide intron 
removal and exon joining. Several studies have focused on identifying the consensus nucleotide 
content of each of these sites. Often times these cis-RNA elements are targets of alternative 
splicing control and are altered in intronic small nuclear polymorphisms (SNPs) that contribute 
to splicing defects associated with human disease.  
1.1.1 Evolutionarily conserved cis-RNA elements 
For the major class of U2 introns, the metazoan 5´ splice site has historically been classified by 
the consensus sequence, (C/A)AG:GU(A/G)AGU (colon, exon-intron junction) (Mount, 1982). 
Here the first GU dinucleotide is invariant and the G at position 8 is highly conserved. U1 small 
nuclear RNA (snRNA) of the U1 small nuclear ribonucleoprotein particle (snRNP) base pairs 
with this RNA element to define the 3´ end of the exon to be spliced (Zhuang and Weiner, 
1986). The strength of an individual 5´ splice site is therefore a direct reflection of its match to 
the consensus sequence and ability to base pair with U1 snRNA. Recently it has been 
demonstrated that a subset of atypical 5´ splice sites contain the consensus sequence, 
ACA:GTTAAG, which is recognized by U1 snRNA in an atypical register, shifted by one 
nucleotide (Roca and Krainer, 2009). This observation suggests that splice site recognition is 
more flexible than previously thought. Weak 5´ splice sites are generally associated with exon 
skipping and alternative splicing control (Kuo et al., 1991). 5´ splice site mutations that decrease 
splice site strength can cause exon skipping or activate cryptic 5´ splice sites causing intron  
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 Figure 1. Cis-acting RNA elements are intimately involved in the two-step chemical 
mechanism of pre-mRNA splicing. A generic pre-mRNA containing two exons (rectangles: 
E1, E2) flanking an intron sequence (line) with the positions of the 5´ splice site (ss), 3´ ss, and 
branchpoint (BP) adenosine (A) is shown (top). The phosphate (p) and hydroxyl (OH) groups 
involved in catalysis of splicing are also indicated. For splicing, two consecutive chemical 
rearrangements occur resulting in the formation of the spliced E1-E2 and intron lariat products 
(bottom).  
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retention (Treisman et al., 1983; O'Neill et al., 1998). Furthermore, mutations that increase 5´ 
splice site strength have been associated with increased exon inclusion and human disease 
(Hutton, 2001). In yeast, the 5´ splice site is less degenerate and matches the consensus, 
AAG:GUAUGU (Long et al., 1997). 
The metazoan 3´ splice site consensus sequence is YnNYAG:G (Y, pyrimidine; N, any 
nucleotide; colon, intron-exon junction) (Mount, 1982). Yn is referred to as the polypyrimidine-
tract and the AG dinucleotide at the intron-exon junction is invariant. In fact, 98% of mammalian 
U2 introns contain a GU at the 5´ splice site and an AG at the 3´ splice site (Sheth et al., 2006). 
Mutation of the AG dinucleotide at the 3´ splice site can activate cryptic 3´ splice sites, resulting 
in intron retention or partial exon exclusion, often resulting in a shift in the reading frame (O'Neill 
et al., 1998). The yeast 3´ splice site is also less degenerate in that the polypyrimidine-tract 
contains mostly Us rather than Us and Cs as for the metazoan 3´ splice site (Long et al., 1997). 
The branch site resides just upstream of the polypyrimidine-tract and has been 
historically defined by the consensus sequence, UACUAAC (Zhuang et al., 1989). Recently, it 
has been demonstrated that the branch site consensus is more degenerate than previously 
thought, YUNAY (Y, pyrimidine; N, any nucleotide; A, the branchpoint) (Gao et al., 2008). The 
branch site was first identified in yeast where the invariant UACUAAC sequence is recognized 
(Langford and Gallwitz, 1983). U2 snRNA base pairs with the branch site region to specify the 
branchpoint adenosine as discussed below. Furthermore, the branch site is recognized 
sequentially by several factors throughout spliceosome assembly (MacMillan et al., 1994). 
Mutations at the branch site have been associated with activation of cryptic branchpoints (Reed 
and Maniatis, 1985) or exon skipping associated with human disease (Kralovicova et al., 2004). 
It has also been shown that the strength of the 5´ splice site partly controls branch site 
(Grabowski et al., 1991) and 3´ splice site selection (Hoffman and Grabowski, 1992) across the 
exon. 
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The degenerate nature of these splice sites, as well as the large size of mammalian 
introns (~1000 nts) makes it difficult to accurately predict all exons of a gene by sequence 
inspection alone. Furthermore, additional RNA elements, including splicing enhancers, are often 
necessary for precise exon inclusion. Mutations that alter splice site strength change splicing 
patterns and often manifest in disease states (Novoyatleva et al., 2006). Moreover, relaxation of 
splice site strength may have provided a platform for the evolution of alternative splicing events 
(Ast, 2004; Kol et al., 2005). 
1.1.2 Chemical mechanism of pre-mRNA splicing 
Intervening intron sequences and the concept of “splicing” were originally described for 
adenovirus 2 (Ad2) and simian virus 40 (SV40) precursor mRNAs (Berget et al., 1977; Chow et 
al., 1977; Berk and Sharp, 1978a, b). Chemical mechanisms of splicing were initially dissected 
using the enzymatically spliced yeast pre-tRNA and the Tetrahymena self-splicing group I 
introns of pre-rRNA as model systems (Cech et al., 1981; Grabowski et al., 1981; Kruger et al., 
1982; Greer et al., 1983; Peebles et al., 1983). Later, splicing of adenovirus pre-mRNA was 
studied in splicing active HeLa nuclear extracts (Padgett et al., 1983), which led to the discovery 
of the spliceosome. Pre-mRNA splicing follows a two-step chemical mechanism as described in 
Figure 1. First, the free 2´ hydroxyl group at the branchpoint adenosine attacks the 
phosphodiester bond that joins E1 to the intron, resulting in the formation of the lariat intron-E2 
intermediate and a free hydroxyl group at the 3´ end of E1 (Grabowski et al., 1981; Padgett et 
al., 1984; Ruskin et al., 1984; Konarska et al., 1985). Next, the free hydroxyl group at E1 attacks 
the phosphodiester bond at the 3´ splice site that joins the intron to E2, resulting in the formation 
of the spliced E1-E2 and intron lariat products. This transesterification reaction is evolutionarily 
conserved across the self-splicing group II introns of Tetrahymena and the spliceosome-
regulated introns of yeast and metazoan pre-mRNA. Tetrahymena self-splicing group I introns 
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follow a similar chemical mechanism, however, guanosine is used as the branchpoint 
nucleophile rather than adenosine. Taken together, the chemical mechanism of splicing is highly 
conserved and can be catalyzed by evolutionarily diverged processes. For the purpose of this 
study, I will focus on spliceosome-mediated splicing. 
1.2 THE SPLICEOSOME 
The spliceosome is the macromolecular machinery that carries out the chemical mechanism of 
pre-mRNA splicing. The spliceosome was simultaneously identified in yeast as a 40S complex 
intimately associated with pre-mRNAs undergoing splicing (Brody and Abelson, 1985) and as a 
60S complex assembled on Ad2 pre-mRNA in splicing active HeLa nuclear extracts (Grabowski 
et al., 1985). Purification of spliceosomal and pre-spliceosomal complexes and intermediates 
has revealed the vast nature of its RNA and protein components (Grabowski and Sharp, 1986; 
Konarska and Sharp, 1987; Bennett et al., 1992). The spliceosome consists of U1, U2, U4, U5, 
and U6 snRNPs and hundreds of accessory factors (reviewed by (Padgett et al., 1986; 
Luhrmann et al., 1990; Reed, 1996)).  Individual snRNPs are formed from the association of 
both common and unique snRNP associated proteins (SAPs) with U1, U2, U4, U5, and U6 
snRNAs.  
The spliceosome is integral to the splicing process and shares several common features 
with the ribosome (reviewed by (Staley and Guthrie, 1998; Staley and Woolford, 2009)). They 
are both catalytically active ribonucleoprotein (RNP) machines consisting of dynamic RNA-RNA, 
RNA-protein, and protein-protein interactions. They are both highly efficient and accurate and 
able to accommodate diverse RNA substrates with proofreading ability. Furthermore, step-wise 
assembly of the spliceosome and ribosome involve RNA cleavage and ligation reactions, RNA 
and protein rearrangements, and hundreds of accessory factors. These accessory factors 
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include RNA binding proteins that stabilize RNA-RNA interactions, helicases that function to 
reconfigure RNA-RNA and RNA-protein interactions, and GTPases and ATPases that function 
to generate energy needed for conformational transitions. Spliceosome assembly occurs by the 
step-wise association of snRNPs and accessory factors and proceeds through complexes H, E, 
A, B, and C as discussed below and illustrated in Figure 2. Although there is a parallel splicing 
pathway in yeast, the metazoan spliceosome is discussed in detail below. 
1.2.1 Complex H: non-specific RNA binding 
Immediately upon addition of pre-mRNA to an in vitro splicing reaction, complex H forms. This 
complex does not depend on ATP or functional 5´ and 3´ splice sites (Konarska and Sharp, 
1986). It is associated with non-specific binding by mostly heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and is not considered to be part of the functional spliceosome 
(Michaud and Reed, 1991). Unique sets of hnRNP proteins associate with individual pre-
mRNAs, which likely depends on the sequence content and size of the pre-mRNA tested 
(Bennett et al., 1992). Importantly, complex H is not resistant to high salt (250 mM) like the 
spliceosome (Reed, 1990). 
1.2.2 Complex E: splice site recognition and exon definition  
Early (E) complex is the first committed step in the splicing process and forms independently of 
ATP (Michaud and Reed, 1991). Here, the 5´ splice site is recognized and defined by U1 
snRNP (Michaud and Reed, 1991) by direct nucleotide interactions between the 5´ end of U1 
snRNA and the pre-mRNA (Zhuang and Weiner, 1986). U2 snRNP auxiliary factor (U2AF) 
recognizes and defines the 3´ splice site (Reed, 1990). U2AF is composed of a 65 kDa subunit, 
U2AF65, and a 35 kDa subunit, U2AF35. U2AF65 binds to the polypyrimidine-tract through direct 
 7 
 Figure 2. Step-wise assembly of the spliceosome guides RNA rearrangements and 
catalysis for precise intron removal and exon joining. A generic pre-mRNA containing two 
exons (E1, E2) flanking an intron of variable length is shown in the 5´ to 3´ direction (top). The 
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relative positions of the 5´ splice site (ss), branchpoint (BP) adenosine (A), and 3´ ss are 
indicated. For Complex E assembly, U1 snRNP, U2AF, and SF1 bind to the 5´ splice site, 3´ 
splice site, and branch site, respectively. In Complex A, U2 snRNP replaces SF1 at the branch 
site to designate the adenosine to be used as the branchpoint. Complex B1 involves the 
association of U4:U6 and U5 snRNPs and removal of U2AF. In Complex B2, U1 and U4 snRNP 
leave, the spliceosome rearranges, the U2:U6 snRNP complex forms, and the branchpoint 
adenosine attacks the 5´ splice site of the upstream exon. In Complex C1, the 5´ splice site of 
the upstream exon attacks the 3´ splice site of the downstream exon for the formation of the 
lariat intron intermediate and ligated mRNA product in Complex C2. After splicing, the lariat 
intron intermediate is debranched and degraded and all the components of the spliceosome are 
recycled. ATP-dependent steps are indicated. 
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interactions with its RNA binding domain (RBD) (Zamore et al., 1992) and U2AF35 associates 
with the 3´ splice site through interactions with U2AF65 (Zhang et al., 1992). Splicing factor 1 
(SF1) makes direct contacts with the branch site region and buries the branchpoint adenosine in 
a hydrophobic cleft (Abovich and Rosbash, 1997; Liu et al., 2001). The U1 snRNP-specific 
proteins U1 A, U1 C, and U1 70K, the snRNP core proteins B and B´, and the 115, 92, 88, 72, 
and 42 kDa SAPs also associate with the pre-mRNA during complex E assembly (Reed, 1990). 
Furthermore, members of the serine and arginine (SR)-rich family of protein factors, which are 
characterized by a domain of repeating serine/arginine dipeptides (termed RS domain), also 
associate during this step. SR factors are important for mediating protein-protein interactions 
through their RS domains and have essential roles in general splicing as well as diverse roles in 
specifying alternative splicing patterns (Fu, 1995). 
Binding by U1 snRNP and U2AF to the 5´ and 3´ splice sites, respectively, defines the 
exon as the unit of RNA to be spliced as indicated by the exon definition model first described 
by Robberson et al. (1990). In support of this model, SR protein factors interact across the exon 
to promote exon definition (Kohtz et al., 1994; Staknis and Reed, 1994a). For example, the SR 
protein, ASF/SF2 (alternative splicing factor/splicing factor 2), has been shown to interact 
simultaneously with the U1 70K component of U1 snRNP (Wu and Maniatis, 1993; Kohtz et al., 
1994) and the RS domain of U2AF35  (Wu and Maniatis, 1993). The SR protein, SC35, was 
shown to carryout similar cross exon interactions (Wu and Maniatis, 1993). Furthermore, 
because it is the first committed step in the splicing process, exon definition is a particularly 
sensitive mechanism to specify alternative splicing patterns (Robberson et al., 1990; Kuo et al., 
1991). 
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1.2.3 Complex A: branchpoint selection 
During complex A assembly, U2 snRNP interacts with the branch site in an ATP-dependent 
manner (Konarska and Sharp, 1987; Jamison and Garcia-Blanco, 1992). U2 snRNA base pairs 
with the branch site region to form a bulged duplex, with the branchpoint adenosine unpaired, 
thereby presenting the adenosine to be used as the nucleophile in the first step of the splicing 
reaction (Query et al., 1994). Interaction of U2AF65 with the polypyrimidine tract, positions the 
basic residues of its RS domain at the branchpoint (Valcarcel et al., 1996). The positive nature 
of this domain neutralizes the negative charge of the phosphate backbone of the snRNA-pre-
mRNA complex and therefore facilitates the U2 snRNA-branch site interaction. Furthermore, 
SAP155 of U2 snRNP interacts with the RS domain of U2AF65 and positions U2 snRNP to the 
branch site by interacting with nucleotides flanking the branchpoint (Gozani et al., 1998). In fact, 
SAP155 replace SF1 (Berglund et al., 1998), thereby allowing the branchpoint to be accessible 
by the splicing machinery.  
In addition to SAP155, SAPs 145, 130, 114, 62, 61, 49, and 33 and U2 snRNP-specific 
proteins A´ and B´´ associate in complex A (Bennett et al., 1992). SAP114, 62, and 61 are 
considered SF3a and 155, 145, 130, and 49 are considered SF3b. These proteins bind 
approximately 20 nucleotides upstream of the branch site in a non-specific manner and also 
function to tether U2 snRNP to the branch site (reviewed by (Will and Luhrmann, 1997)). 
Moreover, the SR protein, SC35, has been shown to mediate interactions between U1 and U2 
snRNPs for cross intron communication of the spliceosome (Fu and Maniatis, 1992). Note that 
sometime after complex A assembly, U2AF disassociates from the pre-mRNA (Bennett et al., 
1992). 
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1.2.4 Complex B: chemical step 1 
During complex B, the tri-snRNP particle, composed of U5 and U4/U6 snRNPs associates with 
the spliceosome (Bindereif and Green, 1987; Konarska and Sharp, 1987; Jamison et al., 1992). 
At this time, the catalytically inactive pre-spliceosome is converted to the catalytically active 
spliceosome. Furthermore, this step is associated with the lag time observed in an in vitro 
splicing reaction. U4/U6 snRNP enters as a duplex RNA with base pairing between the U4 and 
U6 snRNAs. RNA-RNA rearrangements of the spliceosome lead to the disruption of the U4/U6 
duplex and the release of U4 snRNP (Lamond et al., 1988). This process likely involves the 
activity of an RNA helicase or “unwindase” (reviewed by (Staley and Guthrie, 1998)). At this 
time, the 3´ end of U6 snRNA base pairs with the 5´ end of U2 snRNA, forming a short RNA 
helix (Hausner et al., 1990; Datta and Weiner, 1991; Wu and Manley, 1991) closely positioned 
at the catalytic center of the spliceosome (Madhani and Guthrie, 1992; Sun and Manley, 1995). 
U6 snRNP interaction with the 5´ splice site and U2 interaction with the branch site positions the 
spliceosome to initiate the first catalytic step in splicing (Sun and Manley, 1995). Furthermore, 
U5 snRNP associates with the pre-mRNA at the 5´ and 3´ splice sites to align the pre-mRNA 
substrate for splicing (Wassarman and Steitz, 1992; Wyatt et al., 1992; Sontheimer and Steitz, 
1993). Removal of U4 snRNP occurs at a time concomitant with the formation of the lariat-3´ 
exon intermediate and removal of U1 snRNP (Lamond et al., 1988). In fact, U1 snRNP may 
dissociate at an earlier step after U2 snRNP association or may be less stably bound, because 
it is not detected in purified spliceosomes after U2 snRNP association.  
During complex B assembly, SF4 also associates to help generate an active 
spliceosome (Utans and Kramer, 1990). The 200, 116, 112, 110, and 40 kDa U5 snRNP-
specific SAPs and the 102, 90, 82, 68, 60, 57, and 55 kDa SAPs also associate during this step 
(Bennett et al., 1992). As for the earlier steps in spliceosome assembly, SR proteins have been 
implicated in this step of splicing. For example, SR proteins facilitate the incorporation of the tri-
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snRNP into the spliceosome (Roscigno and Garcia-Blanco, 1995) and have also been 
demonstrated to stimulate base pairing between U2 and U6 snRNAs (Tarn and Steitz, 1995). 
Moreover, several of the tri-snRNP associated proteins contain RS domains (Fetzer et al., 
1997), which may be involved in protein-protein interactions and structural transitions of the 
spliceosome. 
1.2.5 Complex C: chemical step 2 
Complex C is designated by the formation of the 5´ exon and lariat intron-3´ exon intermediates 
from complex B. After the first step of splicing, a second conformational change occurs, which 
results in the release of the lariat intron and ligated exon products. U2, U5, and U6 snRNAs 
remain associated with the lariat intron product (Konarska and Sharp, 1987; Lamond et al., 
1988; Wassarman and Steitz, 1992). In vivo, the lariat product is debranched and degraded and 
the snRNP components are recycled to carryout additional rounds of splicing (Ruskin and 
Green, 1985).  
1.2.6 The catalytic center of the spliceosome 
U6 snRNP has been shown to be closely associated with the 5´ splice site during the first step 
of splicing and the 3´ splice site during the second step, which implicates it in catalysis of the 
splicing reaction (Sawa and Shimura, 1992). In fact, the U2/U6 snRNP has been demonstrated 
to carryout a splicing-like reaction in the absence of protein (Valadkhan and Manley, 2001; 
Valadkhan et al., 2007), suggesting that the spliceosome may itself be a ribozyme like the self-
splicing introns of Tetrahymena pre-rRNA. Conversely, it has been suggested that the highly 
conserved U5 snRNP-associated protein, Prp8, is the catalytic center of the spliceosome 
(reviewed in (Wachtel and Manley, 2009)). Prp8 physically interacts with the 5´ splice site, 3´ 
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splice site, and branch site during various steps of splicing, appears to be involved in the 
transition between the two catalytic steps, and is essential for the spliceosome-catalyzed 
splicing process. This protein also contains an RNase H-like fold that would be ideal for 
facilitating RNA rearrangements for splicing. 
Although the spliceosome has been extensively studied in the past, several questions 
remain. How can the spliceosome recognize such diverse RNA substrates with little sequence 
information and still carryout the precise process of splicing? Is the spliceosome a ribozyme? If 
so, why are so many proteins involved? Do these proteins control the specificity and timing of 
splicing? Furthermore, how do alternative splicing factors interact with the spliceosome to 
specify alternative splicing patterns? 
1.3 MINOR CLASS INTRONS 
So far, our discussion of the spliceosome has been about the major class U2 spliceosome, 
which is associated with the splicing of the major class GT-AG introns. Here, I briefly discuss 
the minor class of AT-AC introns and the U12-containing spliceosome that carries out their 
splicing. The observation that some genes do not contain canonical splice sites and the idea 
that an alternate group of splice sites exist was first discussed by Jackson (1991). This rare 
class of introns contains the 5´ splice site consensus, AUAUCCUU (beginning with the first 
nucleotide in the intron), the 3´ splice site consensus, YCCAC (Y, pyrimidine; ending in the last 
nucleotide of the intron), and the branch site consensus, UCCUUAAC (second A, branchpoint) 
(Hall and Padgett, 1994; Sharp and Burge, 1997).  
The consensus 5´ splice site is complementary to U11 snRNA and the consensus 
branch site is complementary to U12 snRNA. In fact, U11 and U12 snRNAs are the minor class 
counterparts of U1 and U2 snRNAs, respectively (Hall and Padgett, 1996; Tarn and Steitz, 
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1996b). Furthermore, the highly diverged U4 and U6 snRNAs, U4atac and U6atac, are 
associated with this minor class spliceosome (Tarn and Steitz, 1996a). The only major class 
snRNA that is involved in splicing of minor class introns is U5 snRNA (Tarn and Steitz, 1996b). 
As for the major class U6 and U2 snRNAs, U6atac and U12 snRNAs form a duplex RNA (Tarn 
and Steitz, 1996a). The minor class spliceosome catalyzes splicing by the same chemical 
mechanism as the major class spliceosome. The discovery of this minor class spliceosome 
reflects the fundamental requirements for the construction of a catalytically active 
macromolecular machine and provides support for the RNA interactions identified for the major 
class spliceosome. 
Some pre-mRNAs contain multiple U2-type introns but a single U12-type intron. In fact, 
there is approximately one U12-type intron for every 300 U2-type introns, which is consistent 
with the lower abundance of the minor class spliceosome (Sheth et al., 2006). It has been 
demonstrated that removal of U12-type introns occurs slower than removal of U2-type introns 
and is therefore the rate-limiting step in the maturation of a pre-mRNA containing both classes 
of introns (Patel et al., 2002). Therefore, U12-type introns may have evolved as a mechanism to 
regulate timing of gene expression. 
1.4 ALTERNATIVE SPLICING 
Given the degenerate nature of metazoan consensus splice sites, how does the spliceosome 
achieve the specificity needed to accurately define a set of exons and precisely remove an 
intervening intron sequence while maintaining the fidelity of the reading frame? Consensus 
splice sites only contain half of the information needed for proper splice site recognition (Lim 
and Burge, 2001). Furthermore, numerous “decoy” exons exist within large metazoan introns 
that resemble real exons in size and splice site strength (Sun and Chasin, 2000). However, 
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these exons are rarely spliced. Therefore, accessory factors are necessary for proper splicing in 
metazoans. These factors include splicing enhancers that function to aid in the assembly of the 
spliceosome and splicing silencers that function to inhibit spliceosome assembly, often times by 
blocking access to the 5´ and 3´ splice sites. In yeast, the introns are much smaller in size and 
consensus splice sites are far more conserved. Therefore, the yeast spliceosome is sufficient 
for accurate splicing, consistent with the limited use of splicing enhancers and silencers.  
The use of splicing enhancers and silencers to adjust spliceosome assembly and exon 
selection is the process of alternative splicing. In metazoans, spliceosome assembly can 
proceed through multiple pathways leading to silencing (skipping) or enhancement (inclusion) of 
an alternatively spliced exon (cassette exon), or may lead to other types of splicing decisions 
such as mutually exclusive exon selection, alternative 5´ and 3´ splice site selection, or intron 
retention. The tissue- and developmental-specific expression of splicing enhancers and 
silencers tunes splicing patterns in a spatial and temporal manner. The protein diversity 
generated by alternative splicing, in part, provides an explanation for the evolution of complex 
organisms with specialized cell types given a fixed number of genes. In fact, it is estimated that 
92-94% of all genes expressed in human tissues undergo alternative splicing events (Wang and 
Burge, 2008). The Drosophila Down syndrome cell adhesion molecule (Dscam) transcript is one 
extreme example of molecular diversity generated from a single gene by splicing (Schmucker et 
al., 2000). This transcript has the potential to produce 38,016 unique protein isoforms that 
function to generate neuronal circuits during brain development. In simpler cases, one or two 
exons are alternatively spliced to modulate protein properties in specific cell types. 
1.4.1 Cis-regulatory RNA elements 
Exonic splicing enhancer (ESE) and silencer (ESS) and intronic splicing enhancer (ISE) and 
silencer (ISS) elements are RNA sequence motifs that are recognized by alternative splicing 
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factors to tune splicing patterns (reviewed by (Ladd and Cooper, 2002; Wang and Burge, 
2008)). Collectively, these motifs are referred to as splicing regulatory elements (SREs). ESE 
and ESS elements are located within the exons that they regulate and ISE and ISS elements 
are located within the flanking intron sequences in close proximity to the exons that they 
regulate. SREs are typically short and degenerate, present in multiple copies, and are usually 
single-stranded, although secondary structure has been implicated in the function of a few 
elements. These elements provide additional information to the splicing machinery and are 
necessary to specify alternative splicing patterns. The current goal in the splicing field is to 
generate a parts list of regulatory elements that can be used to predict the splicing pattern of an 
exon by sequence inspection alone.  
Large-scale randomization and selection approaches have led to the identification of 
numerous ESE/S and ISE/S sequences that functionally affect splicing patterns. The results of 
these selections have been used to generate ESEFinder (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi) (Cartegni et al., 2003), RESCUE-ESE 
(http://genes.mit.edu/burgelab/rescue-ese/) (Fairbrother et al., 2002), and FAS-ESS 
(http://genes.mit.edu/fas-ess/) (Wang et al., 2004) web servers, which offer databases of 
splicing motifs with search capabilities. These global approaches have generated a catalogue of 
splicing elements that can be useful to predict regulation of individual exons of a gene. 
However, the roles of these regulatory sequence motifs in natural pre-mRNAs is likely 
influenced by the strength of the flanking splice sites, the sequence context, and by the 
expression levels of the regulatory factors, which may vary in different cells or during 
development. Another issue is the copy number of the regulatory motifs. A single motif that has 
a weak effect on splicing can have a strong effect in the presence of additional copies of the 
same or functionally similar motifs.  
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1.4.2 Splicing codes 
Splicing codes are combinations of ESE/S and ISE/S motifs that tune splicing patterns through 
specific interactions with cognate RNA binding proteins (reviewed by (Wang and Burge, 2008)). 
Three criteria can be used to experimentally verify a splicing code for a SRE. (1) Changes in the 
copy number and/or arrangement of the RNA motifs should tune the splicing pattern to a 
significant degree. (2) The splicing code should be functionally transferable to a new splicing 
substrate by gain-of-function. (3) Genome-wide searches for the splicing code should identify 
additional regulatory targets at frequencies greater than random chance. Testing such 
candidates can further refine the code, and may suggest interesting new biological targets.  
1.4.3 Trans-acting protein factors 
RNA binding proteins, including members of the SR, hnRNP, and hnRNP K-homology (KH) 
families, have been shown to regulate alternative splicing events at the level of spliceosome 
function. These splicing factors contact their RNA targets directly by recognition of ESE/S or 
ISE/S elements. Observed splicing patterns are often a result of the dynamic balance of 
enhancing and silencing functions. 
SR splicing factors, such as ASF/SF2, generally enhance exon inclusion and contain an 
RBD together with a characteristic RS domain (reviewed by (Graveley, 2000; Maniatis and 
Tasic, 2002)). These factors are involved in alternative splicing as well as constitutive exon 
inclusion as discussed above for the spliceosome. Upon binding to ESE motifs, SR proteins 
recruit factors such as U1 snRNP or U2AF, or antagonize the effects of splicing silencers to 
facilitate exon definition.  
Proteins in the hnRNP family, such as polypyrimidine-tract binding protein (PTB) or 
hnRNPA1, contain multiple RNA recognition motifs (RRMs) and often promote exon skipping by 
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antagonizing the roles of SR proteins or snRNPs (Choi et al., 1986; Burd et al., 1989; Ladd and 
Cooper, 2002). Nonetheless, some hnRNP family members enhance exon inclusion, such as 
Fox1 and Fox2 (Underwood et al., 2005). Others have dual roles capable of both enhancement 
and silencing, such as members of the CUG binding protein (CUGBP) and ETR3-like family, 
termed CELF factors (Ladd et al., 2001; Zhang et al., 2002). In the KH domain family, the Nova1 
and Nova2 splicing factors have been characterized as dual-functional regulators of alternative 
splicing events for transcripts encoding synaptic functions (Ule et al., 2003; Ule et al., 2005).  
Proteins from the SR and hnRNP families of RNA binding proteins are phosphorylated 
and dephosphorylated to adjust their functions (reviewed by (Stamm, 2007)). Phosphorylation 
can modify the ability of RNA binding proteins to interact with RNA and other proteins, can alter 
subcellular localization, and can influence intranuclear localization. Consequently, such 
adjustments can affect the ability of splicing enhancers and silencers to regulate alternative 
splicing events or may couple splicing to signal transduction pathways. Furthermore, these 
modifications may serve important roles in mechanisms that integrate splicing responses and 
extracellular signaling. The findings that many alternative splicing factors are also involved in 
transcription, polyadenylation, 3´ end formation, nuclear export of mRNAs, nonsense-mediated 
mRNA decay (NMD), and translation indicates that splicing is integrated with other pathways of 
gene expression (reviewed by (Goldstrohm et al., 2001; Long and Caceres, 2009)).  
1.4.4 Mechanisms of alternative splicing regulation 
Although mechanisms of alternative splicing regulation are diverse and largely uncharacterized, 
PTB, Nova, and Fox splicing factors have been extensively studied and serve as good 
examples for regulation. PTB is a widely expressed RNA binding protein that has been well 
studied for its functions to silence neural- and muscle-specific exons in a variety of cell types 
(Zhang et al., 1999). PTB and PTB isoforms bind to pyrimidine-rich motifs related to the core 
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sequence, UCUU, through four RRMs to silence alternative exons (Wagner and Garcia-Blanco, 
2001; Spellman and Smith, 2006). PTB is best characterized for its role in silencing the neural-
specific NI exon of the tyrosine kinase, c-src, in nonneuronal cells (Black and Grabowski, 2003). 
PTB silences the NI exon by binding to motifs in the flanking introns to loop out the exon and 
block access of the splicing machinery to the splice sites. PTB can also bind near the 3´ splice 
site of an alternative exon to antagonize U2AF65 binding (Singh et al., 1995) or to sequester the 
branch site (Ashiya and Grabowski, 1997). It can also silence an exon by propagating across 
the RNA to antagonize binding of splicing enhancers and the general splicing machinery 
(Wagner and Garcia-Blanco, 2001). Furthermore, two recent studies have demonstrated that 
PTB can silence alternative exons by inhibiting exon and intron definition events (Izquierdo et 
al., 2005; Sharma et al., 2005). Thus, PTB is a remarkably versatile splicing silencer. 
Mechanisms of splicing silencing and enhancement by Nova proteins have also been 
studied at the level of spliceosome assembly. Nova1 and Nova2 are brain-specific RNA binding 
proteins that were first identified as target antigens in the neurological disorder, paraneoplastic 
opsoclonus-myoclonus ataxia (Buckanovich et al., 1993). Nova proteins have 3 KH-type RBDs, 
which recognize consensus YCAY motifs (Y, pyrimidine) to enhance or silence splicing of 
alternative exons (Dredge and Darnell, 2003; Dredge et al., 2005). The interaction of Nova with 
an ESS inhibits binding of U1 snRNP to the adjacent 5´ splice site (Ule et al., 2006). However, 
when Nova binds to an ISE downstream of an alternative exon, this interaction promotes 
assembly with U2 snRNP. It is likely that the positioning of SREs in the pre-mRNA influences 
the functions of splicing factors (Dredge et al., 2005). 
The mammalian Fox proteins are homologs of the Caenorhabditis elegans feminizing 
gene on X protein. Mammalian Fox family members, Fox1 and Fox2, are expressed in neurons 
of the adult brain and function as enhancers of brain-specific exons that have Fox binding sites 
in their downstream intron. Fox1 and Fox2 bind to a short but specific consensus motif, 
UGCAUG, and function to activate splicing of an alternative exon (Underwood et al., 2005). 
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Fox1 has been characterized for its function as a splicing enhancer of the NI exon of the c-src 
transcript (Underwood et al., 2005). Fox1 binds downstream of the NI exon at a conserved 
UGCAUG hexamer in a way that is thought to antagonize the splicing silencer, PTB. Like Nova, 
Fox proteins can also act as splicing silencers when bound to the intron upstream of an 
alternatively spliced exon (Fukumura et al., 2007). 
Taken together, alternative splicing factors are remarkably versatile proteins that contact 
SREs to tune splicing patterns in a tissue-specific manner. These factors often have different 
effects on spliceosome assembly depending on the position and sequence context of their 
cognate RNA binding sites. Furthermore, competition and cooperation of alternative splicing 
factors acting on the same pre-mRNA creates a tug-of-war for splicing regulation. Still a 
common characteristic of these RNA binding proteins is that they recognize short and 
degenerate sequence motifs, which once again raises the question of how splicing factors can 
accurately select the correct target exons for regulation.  
1.4.5 Regulation of tissue- and developmental-specific expression of splicing factors 
In recent years, several alternative splicing factors have been characterized for having unique 
features that contribute to their tissue- and developmental-specific expression and functions. It 
is becoming clear that these features are more common than once thought and may actually be 
characteristic of most alternative splicing factors. These characteristics include alternative 
splicing within the splicing factor transcript, autoregulation and NMD, cross-regulation of family 
members, and regulation by micro RNAs (miRNAs). Several examples are described below.  
Many alternative splicing factors are themselves alternatively spliced to generate several 
protein isoforms that carryout distinct functions in specific cell types. For example, mammalian 
Fox1 and Fox2 transcripts are extensively alternatively spliced to generate multiple protein 
isoforms (Underwood et al., 2005). Skipping of one exon within Fox transcripts from both genes 
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deletes essential amino acid residues in the protein to eliminate RNA binding activity (Nakahata 
and Kawamoto, 2005). In this way, alternative splicing of splicing factor transcripts can be used 
to regulate their function. 
Furthermore, many alternative splicing factors regulate their own expression and activity 
by controlling alternative splicing of exons within their own transcript. For example, Nova1 has 
the ability to silence an exon within its own transcript (Dredge et al., 2005). The peptide 
segment corresponding to this exon is phosphorylated in vivo and may serve as a localization 
signal or to modulate protein function. Furthermore, many factors from the SR family of splicing 
enhancers have been shown to increase inclusion of an exon within their own transcript to 
cause a shift in the reading frame revealing a premature termination codon (PTC) that targets 
the transcript for NMD (Ni et al., 2007). NMD is a quality control process that selectively 
degrades mRNAs containing PTCs to control for genetic and splicing errors and regulate protein 
expression (Chang et al., 2007). Conversely, several splicing silencers have been shown to 
function by the opposite mechanism to cause skipping of an exon within their own transcript to 
expose a PTC (Wollerton et al., 2004; Baraniak et al., 2006). Therefore, NMD is a process 
utilized by splicing factors to control their own protein levels in the cell. 
Additionally, cross-regulation of closely related family members has been shown for 
several splicing factors. In the nervous system, cross-regulation between PTB family members 
drives mutually exclusive isoform expression in different cell types. In the mouse brain, neural 
PTB (nPTB) is exclusively expressed in neurons, while PTB expression is restricted to glial cells 
(Boutz et al., 2007b). One explanation for this mutually exclusive pattern of expression is that 
PTB causes skipping of an exon in the nPTB transcript by a mechanism similar to 
autoregulation to target the transcript for NMD. PTB and nPTB regulate distinct, yet overlapping 
sets of exons and their cell-specific expression is associated with the differentiation of neuronal 
and glial cells during brain development. 
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The expression of PTB is also regulated through post-transcriptional events involving 
miRNAs. miRNAs are a well studied group of ~22 nucleotide RNAs that bear complimentarity to 
sequences in the 3´ untranslated regions (UTRs) of certain mRNAs where their interactions 
either repress protein synthesis or promote mRNA decay (He and Hannon, 2004). The neuron-
specific miRNA, miR-124, inhibits expression of PTB during neuronal differentiation (Makeyev et 
al., 2007). Decrease in PTB expression leads to an increase of nPTB expression, which is 
associated with a global switch from non-neuronal to neuronal splicing patterns. Furthermore, a 
role for miR-133 in the regulation of nPTB expression has been demonstrated in differentiating 
muscle cells (Boutz et al., 2007a).  
Taken together, these characteristics suggest that global patterns of alternative splicing 
can be controlled in different cell types and during development by several different quality 
control mechanisms. How other splicing factors are targets of such regulation is still to be 
investigated.   
1.5 THE NMDA R1 RECEPTOR 
In the nervous system, alternative splicing greatly expands protein diversity and is necessary for 
neural development and shaping the synapse for processes such as learning and memory. 
Here, alternative splicing is generally the rule rather than the exception. The N-methyl-D-
aspartate (NMDA) receptor NR1 subunit is just one example. NMDA receptors are calcium 
permeable glutamate receptors present at the postsynaptic membrane of excitatory synapses in 
the mammalian central nervous system. These receptors are important for neuronal survival 
and learning and memory, while abnormalities in receptor activity have been implicated in 
neurological disorders. These receptors allow calcium influx that regulates signaling pathways 
involved in synaptic plasticity in response to the binding of glutamate and glycine under 
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depolarizing conditions. Alternative splicing of the NR1 subunit of this receptor has been shown 
to modulate receptor function in a brain region-specific manner and in response to cell 
excitation. 
1.5.1 Brain region-specific alternative splicing 
Alternative splicing of three exons of the NR1 subunit of the NMDA receptor pre-mRNA (GRIN1 
gene) generates eight receptor isoforms with different functional characteristics (reviewed by 
(Zukin and Bennett, 1995; Cull-Candy et al., 2001)). The NI cassette exon (Ensembl transcript 
GRIN1-002, exon 3b), which encodes a portion of the extracellular domain, modulates receptor 
sensitivity to zinc ions, protons, and polyamines. The CI cassette exon (GRIN1-002, exon 19), 
which encodes an intracellular region, regulates membrane localization of the receptor and 
intracellular signaling from the receptor (Ehlers et al., 1995; Okabe et al., 1999; Bradley et al., 
2006). In addition, mutually exclusive splicing of C2 and C2´ exons adjusts receptor trafficking to 
the synapse (Mu et al., 2003). Thus, alternative splicing fine-tunes NMDA receptor properties.  
The brain region-specific splicing factor, CUGBP2 (also called NAPOR, CELF2, ETR3, 
or BRUNOL3), silences the NI exon and enhances the CI exon of the GRIN1 transcript (Zhang 
et al., 2002). These dual functions in splicing regulation, together with the forebrain-enriched 
and hindbrain-deficient pattern of protein expression, are thought to account for the natural 
distribution of NR1 isoforms in the brain (Figure 3). That is, the NI exon is mostly skipped and 
the CI exon is mostly included in the forebrain as directed by the presence of CUGBP2, 
whereas both of these splicing events switch to the opposite patterns in the hindbrain because 
of an absence of CUGBP2. The molecular mechanisms that explain the dual functions of 
CUGBP2 are not yet understood. Although it’s RNA binding motifs have been found in the 
introns downstream from the CI exon and upstream from the NI exon, functionally significant 
motifs in these regions have yet to be identified. 
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 Figure 3. Model for brain region-specific splicing of the NMDA NR1 receptor transcript. 
The GRIN1 pre-mRNA is shown with the NI and CI cassette exons indicated in pink and the 
flanking exons in blue. The broken line indicates a gap in the sequence. In the forebrain, tissue-
specific CUGBP2 expression drives skipping of the NI exon (silencing) and inclusion of the CI 
exon (enhancement). In the CUGBP2-deficient hindbrain, the opposite pattern of splicing 
occurs. Below, the relative positions of the NI and CI peptide cassettes on the NMDA NR1 
receptor are shown. 
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Alternative splicing of the NI and CI exons is under combinatorial control by RNA binding 
proteins from the SR, hnRNP, and KH families of splicing factors. The dynamic balance of these 
splicing factors in different brain regions determines whether NI or CI will be predominantly 
included or skipped in the population of mature GRIN1 transcripts. The CI exon is enhanced by 
SR family members ASF/SF2 and SC35 (Han et al., 2005), hnRNP H (Han et al., 2005), and the 
KH domain protein, Nova (Ule et al., 2006) in addition to CUGBP2. It is also silenced by hnRNP 
A1 (Han et al., 2005). In each of these cases, known cis-regulatory motifs within the exon and 
downstream intron have been shown to contribute to regulation. Furthermore, the NI exon is 
silenced by CUGBP2, PTB, and Nova splicing factors (Zhang et al., 2002) and potentially 
enhanced by Fox family members (unpublished data). The NI and CI cassette exons are 
representative examples of the complex regulation of an exon by multiple factors, which leads to 
the fine-tuning of its tissue- and developmental-specific protein activities (Black and Grabowski, 
2003). 
1.5.2 Alternative splicing in response to neuronal excitation 
Recent studies have shown that the CI cassette is an inducible exon in living cells, since its 
splicing pattern shifts to predominant exon skipping after membrane depolarization or as a 
consequence of overexpression of a constitutively active form of Ca2+/calmodulin-dependent 
protein kinase (CaMK) IV (An and Grabowski, 2007; Lee et al., 2007). The CI exon encodes an 
intracellular peptide region that is believed to mediate intracellular signaling from the cell 
membrane to the nucleus. In this way, the decrease in CI exon inclusion may be part of a 
feedback loop that reduces signaling in neurons to stabilize neuronal excitability during chronic 
excitation. Furthermore, this depolarization-induced skipping pattern is reversed upon removal 
of membrane depolarization (An and Grabowski, 2007), indicating that splicing patterns are 
plastic and probably involved in maintaining cellular homeostasis. 
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The observation that splicing of the CI exon in the nucleus is responsive to cell excitation 
at the membrane implicates a signaling pathway to transfer the message. Notably, specific 
antagonists of the NMDA receptor and several cell permeable inhibitors of signal transduction 
pathways, including Protein Kinase A and CaMKs, were found to attenuate splicing 
responsiveness in the primary neurons (An and Grabowski, 2007). These findings suggest that 
one or more signaling pathways from NMDA receptors located at the membrane to factors in the 
nucleus are responsible for inducing changes at the level of splicing of the CI exon.  
hnRNPA1 has been implicated as the depolarization-responsive splicing factor involved 
in this signaling event (An and Grabowski, 2007). In support of this, additional responsive exons 
have been shown to contain hnRNPA1 silencing elements. However, it is not clear how the 
activity of hnRNPA1 is modified in response to cell excitation. Furthermore, two types of CaMK 
IV-responsive RNA elements (CaRREs) have been found within the CI exon. One element is 
similar to an element defined previously in the 3´ splice site region of the responsive STREX 
exon of the BK channel (Xie et al., 2005). Genome-wide searches for additional exons that 
contain CaRREs have identified CaMK IV-responsive exons in transcripts with functions such as 
calcium homeostasis, intracellular signaling, and vesicular transport. Still, the protein factors that 
recognize such elements have yet to be identified. 
Together these studies highlight the importance of conserved sequence elements in the 
regulation of cellular responsiveness of groups of co-regulated exons, but this work is in an 
early stage. Many questions remain about the nature of the signal transduction pathways 
involved in conveying information from the cell membrane to splicing factors in the nucleus, and 
the nature of the landscape of responsive exons that has yet to be fully characterized. The 
extent to which the induced splicing changes reflect corresponding changes at the protein level, 
as opposed to biological noise, is also not known. A recent study has described the RNA 
splicing capacity of neuronal dendrites in hippocampal cultures (Glanzer et al., 2005). Although 
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speculative, this raises the question of whether certain mRNAs with one or two unspliced introns 
might be targeted to dendrites for local splicing in response to changes in synaptic activity. 
1.6 CUGBP2 
CUGBP2 is a member of the CELF family of hnRNP RNA binding proteins that has been 
characterized for its role in the regulation of tissue-specific splicing events in accordance with 
brain region- and muscle-specific expression during development. Misregulation of CUGBP2 
has been associated with global splicing defects contributing to disease phenotypes of myotonic 
dystrophy type 1 (DM1). CUGBP2 consists of three RRMs and a divergent domain of unknown 
function and has been shown to bind to GU-rich sequence motifs to either silence or enhance 
exon selection. However, the mechanisms of regulation are currently uncharacterized.  
1.6.1 The CELF family of RNA binding proteins 
CUGBP2 is a member of the larger family of CELF RNA binding proteins. Currently, in 
mammals, there are six known family members, CUGBP1, CUGBP2, CELF3, CELF4, CELF5, 
and CELF6 that differ in their unique functions and tissue-specific expression patterns (Good et 
al., 2000; Ladd et al., 2001). CUGBP1 is ubiquitously expressed while expression of CELF3 and 
CELF5 is restricted to the brain. CUGBP2 is expressed in heart, muscle, and brain tissue and 
CELF4 and CELF6 are expressed in a subset of tissues.  CUGBP2 is most closely related to the 
CUGBP1 family member and in fact share many overlapping functions.  
CELF proteins have three RRMs that contact RNA in a sequence-specific manner and a 
variable divergent domain of unknown function (Figure 4). The RRM is a simple but widely used  
 28 
 
Figure 4. Predicted tertiary structure of CUGBP2. (A) Side-view of the CUGBP2 tertiary 
structure predicted using the InterProScan software (EMBL-EBI). Snapshots of the PDB 
structure were taken with the interactive molecular graphics program, VMD. The predicted 
positions of α-helices (pink), β-sheets (yellow), and unstructured regions (blue) are indicated on 
RRMs 1, 2, and 3 and the divergent domain (DD). Relative positions of the x-, y-, and z-axes 
are shown for comparison. (B) Bottom-view of the CUGBP2 structure in (A). Note that this is a 
predicted structure of CUGBP2 and is likely different than the actual structure of the protein.  
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domain consisting of a βαββαβ topology that can fold in different conformations to recognize 
unique RNA or protein substrates (reviewed by (Maris et al., 2005)). The RRM provides high 
specificity in the selection of target substrates and the use of multiple RRMs increases the 
specificity and affinity of binding by a single protein. CUGBP1 and 2 RRMs contact GU-rich 
sequences as indicated by a number of biochemical and functional studies (Takahashi et al., 
2000; Suzuki et al., 2002; Faustino and Cooper, 2005; Marquis et al., 2006). However, specific 
nucleotide motifs recognized by each of these proteins have yet to be identified. It is likely that 
each of these proteins regulates a distinct, yet overlapping group of target exons by slight 
variations in their binding abilities.  
CUGBP2 protein isoforms differ in their N-terminal amino acid sequence by the use of 
alternative start codons and in the divergent domain by alternative splicing (Li et al., 2001). 
Three isoforms are known to exist including NAPOR1, NAPOR2, and NAPOR3. For the purpose 
of this study, I will focus on the NAPOR1 isoform of CUGBP2. How these isoforms differ in RNA 
binding or splicing regulation is currently unknown. 
1.6.2 Brain region-specific expression in the central nervous system  
Brain-specific expression of CUGBP2 is restricted to the forebrain, particularly the cerebral 
cortex, where CUGBP2 carries out functions associated with neuronal cell differentiation and 
development of the nervous system in addition to adjusting modular receptor properties at the 
synapse (Choi et al., 1999; Good et al., 2000; Li et al., 2001; Levers et al., 2002; Zhang et al., 
2002; Choi et al., 2003). CUGBP2 expression is enriched in post-mitotic differentiating neurons 
during embryogenesis and early postnatal life (Choi et al., 1999; Levers et al., 2002).  However, 
expression is deficient in undifferentiated proliferative cells. Therefore, the cell type-specific 
expression of this splicing factor likely contributes to unique splicing patterns in differentiated 
neurons. RNA microinjection studies in zebrafish embryos have demonstrated that 
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overexpression of CUGBP2 results in severe developmental defects in the nervous system 
(Choi et al., 2003). At the synapse, brain region-specific expression of NMDA receptor NR1 
subunit isoforms is closely correlated with CUGBP2 expression and regulation (discussed 
above). Taken together, these observations suggest that CUGBP2 carries out essential 
functions in the central nervous system that are tightly controlled by its brain region- and cell 
type-specific expression patterns. 
1.6.3 Regulation of heart- and muscle-specific exons during development 
CUGBP2 has also been characterized for its muscle-specific expression and roles in muscle 
and heart development (Good et al., 2000; Li et al., 2001; Suzuki et al., 2002; Gromak et al., 
2003; Ladd et al., 2005; Kalsotra et al., 2008). CUGBP1 and 2 function as splicing enhancers of 
cardiac troponin T (cTNT) exon 5 by binding to GU-rich motifs downstream from the exon (Ladd 
et al., 2005). Here, enhancement is associated with competition with the PTB and muscleblind-
like (MBNL) splicing silencers. More recently it has been demonstrated that CUGBP2 interacts 
with protein components of U2 snRNP across the exon to facilitate branch site recognition at the 
upstream intron (Goo and Cooper, 2009). Furthermore, cTNT exon 5 inclusion in the developing 
heart is associated with CUGBP1 and 2 expression, while exon 5 skipping in the adult heart is 
associated with a deficiency of these factors (Ladd et al., 2005). Additional studies have shown 
that this postnatal switch in CUGBP1 and 2 expression is associated with over 30 splicing 
events during heart development (Kalsotra et al., 2008). Furthermore, CUGBP1 and 2 have 
been implicated in the mutually exclusive selection of a set of exons in the α-actinin transcript 
(Suzuki et al., 2002; Gromak et al., 2003). The SM (smooth muscle) exon is repressed in most 
cell types by PTB, while the NM (nonmuscle) exon is included. In muscle cells, expression of 
CUGBP1 and 2 drives skipping of the NM exon by an uncharacterized mechanism and inclusion 
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of the SM exon in part by competition with PTB. Therefore, regulation by the CUGBP1 and 2 
splicing factors drives exon selection in a tissue- and developmental-specific manner. 
1.6.4 Gain-of-function in DM1: from splicing defects to disease phenotypes 
DM1 is an autosomal dominant neuromuscular disease associated with a (CTG)n repeat 
expansion in the 3´ UTR of the myotonin protein kinase (Mt-Pk) gene. These repeats have been 
shown to sequester CUGBP1 and 2 in the nucleus, resulting in a gain-of-function of protein 
activity by an unknown mechanism (Timchenko et al., 1996; Timchenko et al., 2001b; Wang et 
al., 2007). Defects in CUGBP1 and 2 splicing regulation contribute to the multisystemic disease 
phenotypes in patients with DM1 (Timchenko et al., 2004). Additional defects result from a loss-
of-function of MBNL splicing factors and gain-of-function of hnRNPH (Paul et al., 2006). 
CUGBP1 and 2 gain-of-function has been associated with an increase in cTNT exon 5 
inclusion (Philips et al., 1998). cTNT is the heart-specific tropomyosin-binding subunit of the 
troponin complex, which is located on the thin filament of striated muscle and regulates muscle 
contraction in response to endogenous calcium levels. The increased expression of the fetal 
isoform, which includes exon 5, in the adult heart, may be associated with reduced myocardial 
function and conduction abnormalities observed in patients with DM1.  
Loss of expression of the muscle-specific chloride channel, ClC-1, in patients with DM1 
is associated with CUGBP1 gain-of-function and aberrant splicing of ClC-1 pre-mRNA (Charlet 
et al., 2002b). CUGBP1 and possibly CUGBP2 gain-of-function cause aberrant intron inclusion 
in the ClC-1 transcript by binding to an intronic element near the 3´ splice site of the retained 
intron. Intron retention results in a shift in the reading frame, which reveals a PTC that likely 
targets the aberrant transcript for NMD. ClC-1 is the major skeletal muscle chloride channel that 
is localized to the sarcoplasmic reticulum where it is responsible for chloride conductance and 
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stabilizing membrane potential. Defects in this channel are greatly associated with myotonia and 
likely contribute to muscular defects of DM1. 
Functional defects of CUGBP1 and 2 have also been associated with increased skipping 
of the insulin receptor (IR) exon 11 (Savkur et al., 2001; Han and Cooper, 2005; Paul et al., 
2006). CUGBP1 gain-of-function reduces exon 11 inclusion as a result of binding to an intronic 
element near the 3´ splice site (Savkur et al., 2001). Increased expression of insulin receptor 
isoforms that lack the corresponding peptide cassette is associated with the decreased 
metabolic response to insulin in patients with DM1. CUGBP2 likely silences this exon through 
similar intronic elements (Han and Cooper, 2005). Recently, it has been demonstrated that IR 
exon 11 is under coordinate regulation by the silencing effects of CUGBP1 and hnRNPH and 
enhancing effects by MBNL1 (Paul et al., 2006). Therefore, a combination of hnRNPH and 
CUGBP1 and 2 gain-of-function and MBNL1 loss-of-function contributes to the splicing defects 
of IR exon 11 associated with DM1. 
Patients with DM1 also exhibit splicing defects in the central nervous system. CUGBP2 
regulates the microtubule-associated protein Tau (MAPT) exons 2/3 splicing. As a result of 
CUGBP2 gain-of-function in DM1, MAPT exons 2/3 are excluded more often (Leroy et al., 
2006). MAPT mutations have been associated with a number of neurological disorders including 
Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and 
progressive supranuclear palsy. Therefore, collective splicing defects in the MAPT and NMDA 
receptor NR1 subunit transcripts as a result of CUGBP2 gain-of-function likely contribute to the 
cognitive problems observed in DM1 patients. 
In addition to its roles as a splicing regulator, CUGBP2 has been shown to function in 
post-transcriptional events such as mRNA stabilization, translational silencing, and RNA editing 
(Good et al., 2000; Anant et al., 2001; Mukhopadhyay et al., 2003a). In the cytoplasm, CUGBP2 
has been shown to regulate the cell cycle and apoptosis through translational silencing of the 
COX-2 transcript (Mukhopadhyay et al., 2003a; Mukhopadhyay et al., 2003b). Sequestration of 
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CUGBP1 and 2 in the nucleus in DM1 is associated with a decrease of these proteins in the 
cytoplasm and a loss-of-function in the regulation of cytoplasmic events (Timchenko et al., 
2001a). This has been associated with defects in the differentiation of muscle cells because 
CUGBP1 and 2 are not able to enter the cytoplasm to simulate cell cycle withdrawal. Taken 
together, a combination of cytoplasmic and nuclear RNA processing events are regulated by 
CUGBP1 and 2 and misregulation of these events by a gain-of-function in the nucleus and loss-
of-function in the cytoplasm contribute to the global mRNA defects associated with the disease 
phenotypes of DM1. 
1.7 THESIS GOALS AND OBJECTIVES 
Above, I described the current state-of-progress of the splicing field in great detail. From this 
analysis, it is clear that several fundamental questions remain unanswered. For example, how 
do splicing factors recognize their cognate RNA substrates given the short and degenerate 
nature of SREs? Does a combination of specific RNA interactions facilitated by multiple RRMs 
of a single protein contribute to the high specificity and affinity of splicing factor binding? 
Furthermore, do protein-protein interactions between alternative splicing factors and the core 
splicing machinery help facilitate pre-mRNA recognition? If so, how do such interactions 
negatively or positively affect spliceosome assembly to adjust splicing patterns? With this in 
mind, how can one alternative splicing factor simultaneously function as an enhancer and 
silencer of splicing on different substrates? In the nervous system, how is splicing factor function 
adjusted in response to cell signaling to allow for plasticity in splicing control? Here, the 
mechanisms of splicing regulation by the CUGBP2 splicing factor are studied extensively to 
provide insight into some of these questions. 
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CUGBP2 regulates a complex network of alternative splicing events in a tissue-specific 
and developmentally controlled manner. Furthermore, global splicing patterns are affected by its 
misregulation. However, codes for splicing enhancement or silencing by this factor or the 
mechanisms of regulation have yet to be characterized. I initially set out to study splicing 
silencing and enhancement by CUGBP2 using the NMDA receptor NR1 subunit NI and CI 
cassette exons as model systems with three main objectives in mind. The main goals of my 
thesis were: (1) to identify the functionally significant sequence motifs recognized by the 
CUGBP2 splicing factor for splicing silencing and enhancement of the NI and CI exons, 
respectively, (2) to determine the mechanisms of regulation at the level of spliceosome 
assembly, and (3) to generate a predictive code for splicing regulation that can be applied to 
additional target exons. In the end, I only had time to study splicing silencing by this factor in 
great detail and have used information from the NI exon and other published studies to predict 
how this factor may also function as an enhancer of splicing.  Results from these analyses 
provide insight into the mechanisms of target exon selection and splicing silencing by CUGBP2 
and can be used as a platform for the future analysis of splicing regulation by this factor and 
additional splicing silencers and dual functional regulators. 
The functional domains of CUGBP2 involved in splicing silencing or enhancement have 
been analyzed in the past (Singh et al., 2004). In these studies, truncation mutants starting at 
either end of the protein were used to study splicing enhancement or silencing of a CUGBP2 
target exon. Results from these studies remain inconclusive because of inherent flaws in the 
study design. It is likely that the RRMs and divergent domain act in combination to carryout the 
silencing and enhancing roles of the protein. Furthermore, functional redundancies between 
RRMs make it difficult to determine the role of an individual RRM in the context of a truncation 
mutant. As a side study, I use RRM domain mutants and a biochemical approach to determine 
the nucleotides contacted by individual RRMs. Studies with these mutants give clues to the 
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topology of binding for splicing silencing by CUGBP2 and also provide insight into a potential 
mechanism of splicing enhancement.  
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2.0  MATERIALS AND METHODS 
2.1 PLASMID CONSTRUCTION 
The pMAL-c2x-NAPOR vector for purification of recombinant CUGBP2 was generated by PCR 
amplification of the mouse CUGBP2 open reading frame (ORF) (coding for amino acids 1-484) 
from genomic DNA and insertion into the pMAL-c2x vector (NEB) between the BamHI and 
HindIII restriction sites with the malE ORF encoding the maltose binding protein (MBP) tag at 
the amino terminus. Mutant derivatives, RRM1_2, RRM2_3, and ΔDD were generated from the 
pMAL-c2x-NAPOR vector by PCR amplification and reinsertion between the BamHI and HindIII 
restriction sites of the pMAL-c2x vector backbone. RRM1_2 contained amino acids 1-204, 
RRM2_3 contained amino acids 104-212 and 395-484 separated by the XhoI restriction site 
(nucleotides, CTCGAG; amino acids, LE), and ΔDD contained amino acids 1-204 and amino 
acids 392-484 separated by the XbaI restriction site (nucleotides, TCTAGA; amino acids, SR).  
The mouse CUGBP2 (pcDNA4/NAPOR) and rat PTB (pcDNA4/PTB) in vivo expression 
vectors were described previously (Zhang et al., 2002). The pCI/Nova-1 in vivo expression 
vector was a gift of Robert Darnell (Dredge and Darnell, 2003) and the human 
pcDNA3.1/CUGBP1 (FlyLQ) expression vector was a gift of Thomas Cooper (Charlet et al., 
2002a). For the pcDNA3.1/CUGBP1 vector, CUGBP1 was Flag-tagged at the amino-terminus. 
To generate the DUPNIwt and DUP-CUGBP2 splicing reporters, the cassette exon and flanking 
introns were amplified from rat genomic DNA and inserted between the ApaI and BglII 
restriction sites of the DUP4-1 splicing reporter (Modafferi and Black, 1997). Mutant derivatives 
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were generated using the QuickChange Site-Directed Mutagenesis Kit according to the 
manufacturer’s protocol (Stratagene). The DIPm93wt splicing reporter (An and Grabowski, 
2007) was used to generate DIPNIwt and mutant derivatives. DIPNIwt was generated by 
insertion of a 39 base pair fragment containing the 3´ splice site region of the NI exon at position 
-13 base pairs upstream from the test exon.  
pBSDUPNI and pBSDUP-CUGBP2 wild type and mutant vectors for in vitro transcription 
were generated by PCR amplification from the DUPNI or DUP-CUGBP2 wild type or mutant 
splicing reporters and insertion between the HindIII and EcoRI restriction sites of the pBS- 
phagemid vector (Stratagene). E5-8, E5-10, and E5-15 plasmids were generated in a similar 
manner. The pBSAd1 plasmid for in vitro transcription of Ad1 pre-mRNA was described 
previously (Konarska et al., 1985). Plasmid sequences were confirmed by restriction digestion 
and DNA sequencing.  For detailed plasmid maps see Appendix. 
2.2 CUGBP2 PROTEIN PURIFICATION 
Two-250 ml starter cultures of DH10B Escherichia coli transformed with the pMALc2x-NAPOR 
vector were grown in LB broth containing 10 μg/ml ampicillin. After 16 hours, bacteria were 
diluted 1:10 (500 ml to 5 L) and OD595 was monitored until it reached 0.5-0.6. At this time, IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) was added at a final concentration of 0.3 mM to induce 
MBP-tagged CUGBP2 expression. After two hours, cells were pelleted at 3,500 rpm for 10 
minutes at 4oC in the IEC tabletop centrifuge. The bacteria pellet was stored at -80oC overnight. 
The next day, the pellet was thawed and resuspended in chilled 1X Column Buffer (20mN Tris-
HCl, 200 mM NaCl, 1 mM EDTA, 5 mM β-mercaptoethanol, pH 7.4). For every 1 mg pellet, 10 
ml Column Buffer was added. Bacteria were sonicated with 8, 15 second pulses on setting 3 
while on ice. Sonicated bacteria were pelleted at 9,000 xg for 30 minutes at 4oC in the Sorvall 
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centrifuge to obtain a crude extract (supernatant). Using the BioRad Protein Assay and a bovine 
serum albumin (BSA) standard curve, the protein concentration of the crude extract was 
estimated at OD280. At this time 100 μl crude extract (input) was set aside for SDS-PAGE 
analysis. The crude extract was diluted to 3 mg/ml total protein using 1X Column Buffer.  
The amylose column was prepared by pouring amylose resin into a 2.5 x 20 cm column 
until the packed column volume was 80 ml. The column was washed with 10X Column Buffer, 
followed by 1X Column Buffer until the pH of the flow through was 7.4. Crude extract was 
loaded onto the column and flow through was collected for SDS-PAGE analysis. The column 
was washed with 12 column volumes (960 ml) of 1X Column Buffer overnight. Note that the 
column flow rate was ~2 ml/minute.  MBP-tagged CUGBP2 was eluted from the column by the 
addition of 200 ml 1X Column Buffer containing 10 mM maltose. Fractions were collected and 
assayed with the BioRad Protein Assay as before. Input, flow through, and several fractions 
were separated on a 10% SDS-polyacrylamide gel and stained with Coomassie Blue for protein 
analysis (Figure 5A).  
The most concentrated fractions were pooled together and treated with Factor Xa 
protease (NEB) for 48 hours at 4oC to separate the MBP tag from the CUGBP2 protein. Factor 
Xa was added at a ratio of 1:150 (for example: 44 mg protein/150 = 293 μl Factor Xa). SDS-
PAGE, Coomassie Blue gel analysis was carried out to verify protein cleavage (Figure 5B). The 
MBP/CUGBP2 protein mixture was then dialyzed against 100X volume DLS Buffer (20 mM Tris-
HCl, 25 mM NaCl, 2 mM dithiothreitol (DTT), pH, 8.0) at 4oC using dialysis tubing with a 
molecular weight cut off (MWCO) of 3,500. Tubing was boiled in 1 L water containing ~2.5 g 
NaHCO3 for 20 minutes and soaked in water overnight before use. After 3 hours, the DLS Buffer 
was replaced and the mixture was dialyzed for an additional 3 hours.  
The diethylaminoethyl (DEAE)-sepharose column was prepared by loading the DEAE-
sepharose resin into a 2.5 x 20 cm column until the packed column volume was 45 ml. The 
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 Figure 5. Recombinant CUGBP2 protein purification. (A) Amylose affinity purification of 
MBP-tagged CUGBP2. SDS-PAGE, Coomassie Blue gel analysis of total protein from input (IP), 
flow through (FT), and eluted fractions 7, 10, 14, 24, and 30. Precision Plus Protein standard, M. 
Molecular weight in kDa at left. (B) Factor Xa cleavage of MBP-tagged CUGBP2. SDS-PAGE, 
Coomassie Blue gel analysis of MBP-tagged CUGBP2 uncut (U) or cut (C) with Factor Xa. The 
relative positions of MBP-tagged CUGBP2, CUGBP2, and the MBP tag are shown at right. (C) 
DEAE sepharose ion-exchange chromatography to separate purified CUGBP2 from the MBP 
tag. SDS-PAGE, Coomassie Blue gel analysis of IP and flow through fractions 4, 8, 12, 16, 20, 
25, 30, 35, and 40. Molecular weights are as follows: MBP-tagged CUGBP2, 91 kDa; CUGBP2, 
51 kDa; MBP-tag, 40 kDa. 
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column was washed with 10X DLS Buffer, followed by 1X DLS Buffer until the pH of the flow  
through was 8.0. The dialyzed protein mixture was passed through the DEAE-sepharose 
column and 6 ml fractions were collected at a rate of ~2.5 ml/minute while washing.  The protein 
concentration in each fraction was estimated using the BioRad Protein Assay and select 
fractions were analyzed by SDS-PAGE (Figure 5C). The most concentrated fractions were 
combined and concentrated using an Amicon ultrafiltration unit with a MWCO of 30,000 
(Rosenberg lab) to obtain a final concentration of at least 0.54 mg/ml or 10 μM. The protein 
solution was separated into 100 μl aliquots, flash frozen in liquid nitrogen, and stored at  -80oC 
until use. CUGBP2 mutant proteins RRM1_2, RRM2_3, and ΔDD, were purified in a similar 
manner.  
2.3 IN VITRO TRANSCRIPTION 
To generate the DNA template for in vitro transcription, plasmid DNA was purified from DH5α E. 
coli using the QIAprep Spin Miniprep Kit (Qiagen) and digested in a 200 μl reaction containing 
10 μg plasmid DNA, 20 μl 10X NEBuffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 
mM magnesium acetate, 1 mM DTT, pH 7.9) and 2 μl EcoRI (40 U) at 37oC overnight. Plasmids 
used for in vitro transcription include: E5-8, E5-10, E5-15, pBSDUPNI, pBSDUPNIm1, 
pBSDUPNIm3, pBSDUPNIm1,2,3, pBSAd1, and pBSDUP-CUGBP2. Complete digestion was 
verified on a 1% agarose gel next to uncut plasmid. Uncut plasmids mostly contained 
supercoiled DNA with less than 10% nicked circle DNA. Cut plasmid DNA was purified by 
phenol/chloroform extraction followed by ethanol precipitation. All DNA pellets were washed 
with 70% ethanol and resuspended in 10 μl sterile ddH2O to obtain a final DNA concentration of 
~1 μg/μl. DNA templates were stored at -20oC until use.  
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In vitro transcription was carried out in a 25 μl reaction containing 1X transcription buffer 
(40 mM Tris-HCl pH 8.0, 8 mM MgCl2, 50 mM NaCl, 2 mM spermidine), 400 μM ATP, 400 μM 
CTP, 400 μM UTP, 400 μM GTP, 30 mM DTT, 1 μg DNA template, 10 U T3 RNA polymerase 
(Stratagene), and 10 U RNasin (Promega). For “hot” transcription, 25 μCi α-32P-UTP (Perkin 
Elmer) was added to the reaction and unlabeled UTP was at a final concentration of 300 μM. 
Importantly, α-32P-UTP was less than two weeks old. Transcription reactions were incubated at 
37oC for 30 minutes before addition of 1.25 U RQ1 RNase-Free DNase (Promega) and 
incubation at room temperature for an additional 10 minutes. Reactions were then loaded onto a 
Sephadex G-25 column generated in 1X New Buffer (50 mM Hepes pH 7.0, 50 mM KCl, 2 mM  
magnesium acetate, 0.1 mM EDTA) with a packed column volume of 3-5 ml. Columns were 
centrifuged at 2,000 rpm at 4oC for 4 minutes in the tabletop IEC centrifuge. Flow through 
containing newly transcribed RNA was collected in a 15 ml conical tube and transferred to a 1.5 
ml eppendorf tube. Free nucleotides were retained in the column. RNA was ethanol precipitated 
in 1/10 volume 3 M sodium acetate, 1/50 volume 10 mg/ml glycogen, and 2.5 volumes 100% 
ethanol on crushed dry ice for 10 minutes followed by centrifugation at 13,000 xg for 10 minutes 
at 4oC. RNA pellets were washed with 70% ethanol and resuspended in 25 μl sterile ddH2O. 
One-thousand cpm radiolabeled RNA was separated on a 10% polyacrylamide 7 M urea gel, 
dried under vacuum, and visualized on a BAS-2500 phosphoimaging system (Fujifilm) to verify 
RNA integrity and size. RNA was stored at -20oC for less than one week before use.  
2.4 NITROCELLULOSE FILTER BINDING ASSAY 
For nitrocellulose filter binding assays, a modified version of the protocol described by Draper et 
al. (1988) was used. RNA substrates were 32P-UTP-labeled by in vitro transcription and used at 
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a final concentration of 1000 cpm/μl (20-100 nM). RNA was heated at 85oC for 5 minutes and 
then cooled to 37oC for 5 minutes to remove long-range secondary structures. Serial dilutions of 
protein (0.1-1.0 μM final concentration) were prepared on ice in binding buffer (50 mM Tris pH 
8.0, 150 mM NaCl, 0.1 mg/ml tRNA, 2 mM DTT, 20 units RNasin (Promega)) in a final volume of 
199 μl. Protein solutions were warmed to 37oC for 5 minutes before adding 1 μl of diluted RNA 
(final RNA concentration 100-500 pM). RNA-protein complexes were assembled in triplicate at 
37oC for 30 minutes before filtration through 25 mm BA85 filters backed by DE81 filters in a 
Millipore 1225 vacuum manifold. Filters were separated and dried at room temperature 
overnight. The cpm retained on the BA85 filter corresponded to RNA bound to protein and the 
cpm retained on the DE81 filter corresponded to free RNA. Bound/total RNA was plotted as a 
function of increasing protein concentration using KaleidaGraph Synergy Software and data 
were fit to a hyperbola to estimate the dissociation constant (Kd) according to the equation 
bound/total RNA = [CUGBP2]/([CUGBP2] + Kd).  
2.5 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
Binding reactions were prepared as described above for the nitrocellulose filter binding assay 
except 50 μl reactions were used and protein-RNA complexes were formed on ice for 1 hour 
followed by the addition 3 μl native loading dye (50% glycerol, 0.1% xylene cyanol, 0.1% 
bromphenol blue). For electrophoretic mobility shift assays (EMSAs), 0.1-4.0 μM final 
concentration protein was used. Free RNA and RNA-protein complexes were separated on a 
5% native polyacrylamide gel (80:1 acrylamide to bis ratio) cast in 50 mM tris-glycine buffer at 
250 volts for 2 hours in the cold room. Gels were dried under vacuum and visualized with a 
BAS-2500 phosphoimaging system (Fujifilm) and ImageGauge software. 
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2.6 CMCT MODIFICATION FOOTPRINTING 
RNA footprinting assays were modified from (Brunel and Romby, 2000). RNA-protein 
complexes were assembled as for the nitrocellulose filter binding assay for 30 minutes at 37oC 
with 0.18 μM unlabeled RNA substrate and purified protein in a final volume of 50 μl. Each 
sample was then combined with an equal volume of 42 mg/ml 1-cyclohexyl-3-(2-
morpholinoethyl)-carbodiimidemetho-p-toluene-sulfonate (CMCT) in BMK buffer (80 mM 
potassium borate pH 8.0, 100 mM NH4Cl) without mixing and chemical modification was carried 
out at 37oC for 7 minutes. Reactions were terminated by ethanol precipitation by the addition of 
2.5 volumes 100% ethanol, 1/10 volume 3 M sodium acetate, and 1/50 volume 10 mg/ml 
glycogen followed by mixing, incubation on crushed dry ice for 10 minutes, and centrifugation at 
13,000 xg for 10 minutes at 4oC. Recovered RNA pellets were resuspended in 200 μl proteinase 
K mix (10 mg/ml proteinase K, 50 mM Tris-HCl pH 7.5, 10 mM EDTA, 10 mM NaCl, 0.2% SDS) 
and incubated at room temperature for 10 minutes.  Proteinase K treatment was followed by 
phenol/chloroform extraction and ethanol precipitation as before. Modified RNA pellets were 
washed with 70% ethanol and resuspended in 10 μl sterile ddH2O.  
Primer extension was carried out in a reaction containing 5 μl modified RNA, 1 μl of 1 
μM 5´32P-labeled primer (see below), 1X First Strand Buffer (50 mM Tris-HCl pH 8.3, 75 mM 
KCl, 3 mM MgCl2), 10 mM DTT, 0.5 mM dNTPs, 10 U RNasin (Promega),  and  100 U 
Superscript II Reverse Transcriptase (Invitrogen) in a final reaction volume of 10 μl at 42oC for 
50 minutes. RNA was recovered by ethanol precipitation by the addition of 45 μl 0.3 M sodium 
acetate, 150 μl 100% ethanol, and 1 μl 10 mg/ml glycogen and incubation on crushed dry ice for 
15 minutes followed by centrifugation at 13,000 xg for 15 minutes at 4oC. RNA pellets were 
washed with 70% ethanol and resuspended in 6 μl formamide loading buffer (97% deionized 
formamide, 0.1% xylene cyanol, 0.1% bromphenol blue). Sequencing ladders were generated 
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from the parent plasmid using Thermo Sequenase Cycle Sequencing Kit (USB) according to 
manufacturer’s protocol. cDNA was heated to 85oC for 2 minutes and 2 μl were separated on a 
10% polyacrylamide 7 M urea gel at 45 watts for 2 hours and dried under vacuum. Gel images 
were recorded on a BAS-2500 phosphoimaging system (Fujifilm) and analyzed with 
ImageGauge software.   
The JBE5-2 (5´-ATAGGACAGTTGGTCGAGGT-3´) and CUGBP2-PE (5´-
TCTGTGCCATTGCCCTGGTAG-3´) primers were 5´32P-labeled with T4 polynucleotide kinase 
(PNK) in a 25 μl reaction containing 20 μM PAGE-purified primer, 10 U T4 PNK (NEB), 1X PNK 
buffer (70 mM Tris-HCl, 10 mM MgCl2, 5 mM DTT, pH 7.6), and 150 μCi γ-32P-ATP (Perkin 
Elmer). Reactions were incubated at 37oC for 30 minutes then loaded onto a Sephadex G-25 
column with a total packed column volume of 3-5 ml. Columns were centrifuged at 2,000 rpm at 
4oC for 4 minutes in the tabletop IEC centrifuge. Flow through containing labeled primer was 
collected in a 15 ml conical tube and transferred to a 1.5 ml eppendorf tube. Free nucleotides 
were retained in the column. Primers were ethanol precipitated in 1/10 volume 3 M sodium 
acetate, 1/50 volume 10 mg/ml glycogen, and 2.5 volumes 100% ethanol on crushed dry ice for 
10 minutes followed by centrifugation at 13,000 xg for 10 minutes. Primer pellets were washed 
with 70% ethanol and resuspended in 20 μl sterile ddH2O to obtain a final concentration of ~1 
μM. Note that JBE5-2 was used for primer extension of the E5-10 RNA substrate and CUGBP2-
PE for the DUP-CUGBP2 RNA substrate. The corresponding primers were also used for the 
generation of sequencing ladders from the parent plasmids. 
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2.7 IN VIVO SPLICING REPORTER ASSAY 
C2C12 and N18TG2 cells were grown in DMEM (Cellgro), 10% (v/v) fetal bovine serum (FBS). 
Twenty-four hours prior to transfection 1.5 x 105 C2C12 cells or 2 x 105 N18TG2 cells were 
seeded on 35 mm plates to achieve 60-80% confluency. For transient co-transfection, 1 μg 
pcDNA4 His/Max vector backbone or 1 μg pcDNA4/NAPOR, pC1/Nova-1, pcDNA4/PTB, or 
pcDNA3.1/CUGBP1 expression vector and 0.25 μg splicing reporter (DUPNIwt, DIPNIwt, DUP-
CUGBP2, or mutant derivatives) were mixed with 250 μl Opti-MEM (Gibco) followed by addition 
of an equal volume of Opti-MEM mixed with 2.5 μl Lipofectamine 2000 (Invitrogen) and 
incubated at room temperature for 20 min. Media on cells was replaced with 1.5 ml DMEM, 10% 
(v/v) FBS prior to transfection. Typically 20-30% of cells were transfected and both plasmids 
entered the same cell. Total RNA was isolated 36 hours after transfection using TRIZOL 
reagent (Invitrogen) according to manufacturer’s protocol.  
Total RNA was reverse transcribed in a reaction containing 2 μg total RNA, 0.5 μg 
random primers (Promega), 0.5 mM dNTPs, 10 mM DTT, 1X First Strand Buffer (50 mM Tris-
HCl pH 8.3, 75 mM KCl, 3 mM MgCl2), and 200 U MMLV Reverse Transcriptase (Invitrogen) in 
a final volume of 20 μl. Reverse transcription (RT) was carried out at 37oC for 1 hour and 
terminated by heat inactivation at 65oC for 10 minutes. Note that the random primers were 
annealed to the total RNA in water by incubation at 65oC for 10 minutes followed by slow 
cooling to room temperature for 10 minutes prior to reverse transcription.  
Polymerase chain reaction (PCR) was carried out in 10 μl reactions containing 1 μl of 
the reverse transcription reaction, 0.1 μM of each primer, 2 mM MgCl2, 0.2 mM dNTPs, and 2.5 
U Taq DNA polymerase (Promega). Forward primers were 5´32P-labeled as described above for 
the CMCT modification footprinting assay. The BGJB1 forward primer (5´-TGG 
TGCATCTGACTCCTGAGG-3´) and BGJB2 reverse primer (5´-CTGGGTCCAAGGGTAGA 
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CCAC-3´) were used for amplification of RNA from the DUPNI and DUP-CUGBP2 wild type and 
mutant splicing reporters and the GFP-f forward primer (5´-AGTGCTTCAGCCGCTACCC-3´) 
and GFP-r reverse primer (5´-GTGTCGCCCTCGAACTTCACC-3´) were used for amplification 
of RNA from the DIPNI wild type and mutant splicing reporters. Cycling parameters were 
adjusted to give amplification in the linear range. Conditions were as follows: initial denaturation 
at 94oC for 2 minutes followed by denaturation at 94oC, 1 minute; annealing at 60oC, 1 minute; 
and elongation at 72oC, 1 minute for 22 cycles with a final elongation step at 72oC for 10 
minutes. PCR samples were resolved on 6% polyacrylamide 5 M urea gels at 30 watts for 1 
hour and 15 minutes and dried under vacuum. Gel images were captured using a BAS-2500 
phosphoimaging system (Fujifilm) and data were quantified using Image Gauge software. The 
profile mode was used to subtract background and calculate percent exon inclusion of individual 
lanes. 
2.8 SDS-PAGE AND WESTERN BLOTTING 
Unless otherwise stated, whole cell lysates were used for Western blot analysis. Whole cell 
lysates were prepared by first growing N18TG2, HEK293T, or C2C12 cells in a 10 cm dish with 
DMEM growth media (Cellgro) supplemented with 10% FBS. Once cells reached 90% 
confluency, media was removed and cells were scraped off the plate in 200 μl SDS-RIPA buffer 
(3 parts RIPA buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% Triton x100), 1 part 2X laemmli (100 mM Tris-HCl pH 6.8, 20% 
glycerol, 4% SDS)). Cells were transferred to a 1.5 ml eppendorf tube and sonicated on setting 
3 for 10 seconds on ice. Cell lysates were flash frozen in liquid nitrogen and stored at -80oC until 
use. Note that I did not check the concentration of cell lysates because they contain SDS. 
Therefore a loading control was used to compare protein levels. 
 47 
For SDS-PAGE analysis, SDS-polyacrylamide gels were prepared with a 4% stacking 
gel mixture cast on top of 10-12% laemmli separating gel (37.5:1 acrylamide to bis ratio). 
Protein samples were prepared by first spinning out cell debris at 10,000 rpm for 2 minutes at 
4oC and then adding 6X SDS-loading buffer (1.0 M Tris-HCl pH 6.8, 30% glycerol, 10% SDS, 
600 mM DTT, 0.012% bromphenol blue) to a final concentration of 1X followed by boiling at 
100oC for 5 minutes. Gels were run in 1X Running Buffer (400 mM glycine, 50 mM Tris-HCl, 
0.1% SDS) until the bromphenol blue ran out of the gel into the bottom reservoir. Gels were 
either stained with Coomassie Blue to assay total proteins or transferred to a nitrocellulose 
membrane for Western blotting. 
For Western blot analysis, proteins were transferred from the polyacrylamide gel to a 
Immobilin-P nitrocellulose membrane (Millipore) at 15 volts overnight. Transfer was confirmed 
by Ponceau S staining. Membranes were blocked in PBST (1X phosphate buffered saline 
(PBS), 0.1% Tween 20) containing 5% milk for 1 hour at room temperature while shaking, 
followed by a quick wash in PBST. Membranes were then incubated in primary antibody for 1 
hour while rotating at 4oC. Primary antibodies were diluted in PBST + 1% BSA as follows: 
αCUGBP2 (1H2), 1:1000; αCUGBP1/2 (3B1), 1:1000; αhnRNPA1 (9H10), 1:2000; αXpress, 
1:3000. Importantly, the 1H2 antibody is highly specific for CUGBP2 (Ladd et al., 2005). 
Membranes were then subjected to four 10-minute washes in PBST at room temperature. After 
washing, membranes were incubated in secondary antibody (1:20,000 dilution of αmouse-HRP 
(Roche) in PBST + 1% BSA) for 1 hour while shaking in the cold room. Membranes were then 
washed as before and treated with Western Lightning Plus-Enhanced Chemiluminescence 
Substrate (Perkin Elmer) for 1 minute before development with the LAS-3000 Intelligent Dark 
Box (Fujifilm) for 1-5 minutes and analysis with ImageGauge software. 
 48 
2.9 CULTURING, TRANSFECTION, AND PROTEIN ANALYSIS OF PRIMARY CORTICAL 
NEURONS 
Two-dozen fresh E18 rat cerebral cortexes (hemispheres) were ordered from Zivic Miller in 
sterile 1X PBS. Immediately after arrival, tissue was gently rinsed three times with 20 ml sterile 
1X PBS (Ca2+, Mg2+ free). Tissue was digested in 20 ml 1X trypsin diluted in trypsin media 
(MEM (Gibco), 0.1% glucose (sterile filtered), 2 mM L-glutamine (sterile filtered, light sensitive), 
20 mM HEPES (Sigma)) at 33-36oC for 20 minutes, tapping the tube gently every 5 minutes. 
After digestion, trypsin was removed and tissue was rinsed three times with 20 ml fresh trypsin 
media. For rinsing, media was added, tissue was allowed to settle to the bottom of the tube for 3 
minutes, and then media was removed. Digested tissue was resuspended in 8 ml trypsin media, 
transferred to a sterile 10 ml syringe, and passed through an 18 gauge needle 8-10 times into a 
10 cm dish to homogenize the tissue. Importantly, tissue was never aspirated into the syringe it 
was only passed out of the needle. After pipetting up and down five times, digested tissue was 
transferred to a 50 ml conical tube. The 10 cm dish was rinsed two times with 10 ml trypsin 
media, which was also added to the conical tube. Homogenized tissue was allowed to sit at 
room temperature for 5 minutes to allow connective tissue and debris to settle to the bottom of 
the tube. The supernatant was transferred to two 15 ml falcon tubes. The pellet containing cell 
debris was rinsed with 30 ml trypsin media and the supernatant of this wash was transferred to 
two more 15 ml falcon tubes. The four tubes were centrifuged at 800-900 rpm for 3-4 minutes 
(setting 4, tissue culture room) to pellet the cells. Cell pellets were washed two times with 5 ml 
growth media (Neurobasal media (Gibco) supplemented with 0.5 mM L-glutamine (sterile 
filtered, light sensitive) and 2% B-27 supplement (Invitrogen)). While washing, pellets were 
combined into one tube. The final cell suspension was turbid without clumps and was 
resuspended in 25 ml growth media containing 200 ng/ml gentamicin. Cells were counted on a 
hemacytometer and 6-10 x 105 cells were plated per well of a 6 well dish and 3 x106 cells were 
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plated per 10 cm dish. Dishes were pre-coated with poly-D-lysine (BD Biosciences). If 
coverslips were used, three poly-D-lysine-coated coverslips (BD Biosciences) were placed into 
each well of an uncoated 6 well dish and 6-10 x 105 cells were plated per well. Half of the 
growth media was replaced after 4 days and primary cortical cultures were incubated in a 37oC 
tissue culture incubator adjusted to 6% CO2. Primary cortical cultures contained mostly neurons 
and few supporting glial cells. 
For splicing reporter analysis in primary cortical cultures, 1 μg pcDNA4 His/Max vector 
backbone and 0.25 μg splicing reporter (DUPNIwt or mutant derivatives) were mixed with 250 μl 
Opti-MEM (Gibco) followed by addition of an equal volume of Opti-MEM mixed with 2.5 μl 
Lipofectamine 2000 (Invitrogen) and incubated at room temperature for 20 min. Media on cells 
was replaced with 1.5 ml Opti-MEM prior to transfection. Typically 10-15% of cells were 
transfected. For this experiment, the pcDNA4 His/Max vector backbone was used as carrier 
DNA. After 5 hours, the Opti-MEM transfection mix was replaced with growth media containing 
200 ng/ml gentamicin. Total RNA was isolated 24 hours after transfection using TRIZOL reagent 
(Invitrogen) according to manufacturer’s protocol. RT-PCR and gel analysis were carried out as 
described in section 2.7. 
Nuclear lysates of primary cortical cultures were prepared from six 5-day-old 10 cm 
dishes. Cells were harvested by scraping them off the plate in 1 ml 1X PBS per plate, followed 
by centrifugation at 800-900 rpm for 3-4 minutes (setting 4, tissue culture room). Cells from all 
plates were pooled into a 15 ml conical tube, resuspended in 4 ml chilled Buffer I (0.32 M 
sucrose, 3.0 mM CaCl2, 2.0 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl pH 8.0, 
0.5% NP-40, 1.0 mM DTT), and incubated on ice for 30 minutes while douncing 9-12 times 
followed by vortexing every 10 minutes. Glass homogenizers were baked and chilled prior to 
use. Cell lysis was verified by trypan blue staining. The lysed cell mixture was overlaid onto 3.5 
ml chilled Buffer II (2M sucrose, 5 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl pH 
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3.0, 1 mM DTT) in an SW41 ultracentrifuge tube (Beckman 331372). Note that protease and 
phosphatase inhibitors can be added to Buffer I and Buffer II to decrease protein degradation. 
Cell lysates were ultracentrifuged at 30,000 xg (~15,500 rpm) for 45 minutes at 4oC. 
Supernatants containing cell debris and cytoplasmic lysate were carefully removed. Nuclei were 
lysed in 150 μl SDS-RIPA buffer (3 parts RIPA buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 
mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton x100), 1 part 2X laemmli (100 mM 
Tris-HCl pH 6.8, 20% glycerol, 4% SDS)) for 30 minutes on ice. Nuclear lysates were 
transferred to a 1.5 ml eppendorf tube on ice, sonicated on setting 3 for 10 seconds, flash 
frozen in liquid nitrogen, and stored at -80oC until use. SDS-PAGE and Western blotting were 
carried out as described in section 2.8. 
2.10 IMMUNOFLUORESCENCE 
Immunofluorescence analysis was carried out with primary cortical cultures grown on poly-D-
lysine-coated coverslips. For all steps, it is important that coverslips are always completely 
covered with liquid and do not dry out. Coverslips were washed two times with 1X PBS and cells 
were fixed with 3.7% formaldehyde in 1X PBS for 7 minutes at room temperature. Note that all 
washes were carried out for 3 minutes each. After fixation, coverslips were washed three times 
with 1X PBS and fixed cells were permeabilized with 0.1% Triton X100 in 1X PBS for 1 minute 
at -20oC followed by 5 minutes at 4oC. Coverslips were then washed three times with Incubation 
Buffer (1X PBS, 1% BSA, 0.1% gelatin, 0.01% sodium azide). Note that the Incubation Buffer 
was prepared by first dissolving gelatin in PBS at 65oC before the addition of BSA and sodium 
azide. Cells were then blocked in Incubation Buffer containing 5% goat serum for 3 hours at 
room temperature, followed by three washes in Incubation Buffer. Coverslips were then 
transferred from the 6 well dish to a humidified chamber (tissue culture dish with parafilm on the 
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bottom of the dish and a piece of damp filter paper on the inside of the lid) for the rest of the 
incubations.  
The appropriate dilution of primary antibody was prepared in Incubation Buffer and 
pipetted onto the coverslips so that the surface of the coverslips were completely covered with 
liquid. Cells were incubated in primary antibody at 4oC overnight. It is important to be extra 
careful that coverslips do not dry out during this step. For co-immunofluorescence, both primary 
antibodies were added at the same time. Primary antibody dilutions were as follows: mouse 
αCUGBP1/2 (3B1), 1:500; mouse αCUGBP2 (1H2), 1:500; rabbit αGFAP (Chemicon), 1:1000; 
rabbit αNeurofilament L (Chemicon), 1:1000. GFAP (Glial Fibrillary Acidic Protein) is a glial cell-
specific marker that is only expressed in the cytoplasm and Neurofilament L (Light) is a neuron-
specific marker that is expressed throughout the cell and nucleus. After incubation in primary 
antibody, coverslips were washed three times with Incubation Buffer as before. 
Next, the appropriate dilution of secondary antibody in Incubation Buffer was pipetted 
onto the coverslips and incubated for 2 hours at 4oC in the dark. Secondary antibody dilutions 
were as follows: Alexa Fluor 488 goat αmouse-IgG (Molecular Probes), 1:500; Alexa Fluor 568 
goat αrabbit-IgG (Molecular Probes), 1:500. All subsequent steps were carried out in the dark. 
Coverslips were washed three times with Incubation Buffer and then incubated in DAPI Nucleic 
Acid Stain (Invitrogen) diluted to 300 nM in 1X PBS for 3 minutes at room temperature. 
Coverslips were subjected to three final washes in 1X PBS and mounted cell-side down onto 
glass slides with 2-5 μl mounting media (see below). Cells were visualized with the confocal 
microscope and 60X oil immersion lens and slides were stored in a dark box at -20oC for future 
reference.  
To prepare mounting media, 2.4 g Mowiol 4-88 (Calbiochem) and 6.0 g glycerol (liquid) 
were diluted in 6.0 ml sterile ddH2O and incubated at room temperature overnight. The next day, 
12.0 ml 0.2 M Tris-HCl was added and the mixture was heated to 50oC for 10 minutes. The 
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mixture was then centrifuged at 5000 xg for 15 minutes. The supernatant was transferred to a 
new tube and 0.6 g DABCO (Sigma) was added. The mixture was then aliquoted and stored at -
20oC until use. 
2.11 PREPARATION OF HELA NUCLEAR EXTRACTS 
HeLa nuclear extract was prepared as described by Dignam et al. (1983). Six liters of HeLa 
spinner cells were grown to a cell density of 3 x 105 cells/ml (~1.8 x 109 cells total). JMEM 
growth media (Sigma) was supplemented with 20 mM Hepes and 24 mM sodium bicarbinate, 
adjusted to pH 7.0, sterile filtered, and then supplemented with 5% horse serum before use. 
Cells were grown in sterile spinner flasks at 37oC. The day before the prep, all buffers were 
prepared without DTT or glycerol and chilled in the cold room, centrifuge rotors and buckets 
were chilled, and glass homogenizers were baked, cooled to room temperature, and chilled in 
the cold room overnight.  
Using 1 L centrifuge bottles, cells were pelleted at 1000 rpm for 10 minutes at 4oC in the 
IEC tabletop centrifuge. The supernatant was carefully discarded and this step was repeated 
until all cells were condensed into one bottle. Note that cells were kept on ice at all times and 
the cell pellet was very loose. Next, the cell pellet was condensed further into one 50 ml conical 
tube by rinsing with 1X PBS. At this time, the packed cell volume (PCV) was 7.5 ml. The pellet 
was resuspended in 5 PCV (37.5 ml) Buffer A (10 mM Hepes pH 7.6, 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT) and incubated on ice for 10 minutes. Cells were then centrifuged at 1500 rpm 
for 10 minutes at 4oC in the IEC tabletop centrifuge and the cell pellet was resuspended in 2 
PCV (15 ml) Buffer A. Next, the cells were dounced with a tight pestle A on ice until ~90% of 
cells were lysed as verified by trypan blue staining.  
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Lysed cells were then quickly transferred to a 50 ml round bottom tube and centrifuged 
at 2000 rpm for 10 minutes at 4oC in the Sorvall centrifuge. The supernatant was removed, set 
aside on ice, and used to generate the S100 extract (see below). Note that the pellet is not very 
distinct from the supernatant. The pellet was centrifuged at 30,500 xg for 20 minutes at 4oC in 
the Sorvall centrifuge. The supernatant from this step was added to the supernatant from the 
last step.  
The nuclear pellet was gently resuspended in 5.4 ml Buffer C (20 mM Hepes pH 7.5, 
25% glycerol, 0.42 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT) by swirling with a pipette 
tip and then rotated at 4oC for 30 minutes for nuclear extraction. Note that Buffer C was added 
at 3 ml/109 cells. The nuclei were then centrifuged at 30,500 xg for 30 minutes at 4oC in the 
Sorvall centrifuge to obtain the nuclear extract (supernatant). Nuclear extracts were dialyzed 
against 1 L Buffer D (20 mM Hepes pH 7.6, 20% glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM 
DTT). Dialysis tubing was 18 mm wide and had a MWCO of 3500. After 2 hours, the Buffer D 
was replaced and the extract was dialyzed for an additional 2 hours. The final protein 
concentration was ~6 mg/ml. Nuclear extracts were divided into 200 μl aliquots, flash frozen in 
liquid nitrogen, and stored at -80oC until use. 
For preparation of the S100 extract, 0.11 volume Buffer B (0.3 M Hepes pH 7.5, 1.4 M 
KCl, 30 mM MgCl2) was mixed with the S100 fraction and centrifuged at 100,000 xg in the 
ultracentrifuge using the SW41 rotor for 1 hour. The supernatant was flash frozen in liquid 
nitrogen and stored at -80oC for future use. 
2.12 IN VITRO SPLICING ASSAY 
pBSDUPNI, mutant derivatives, or pBSAd1 were digested with EcoRI for in vitro transcription in 
the presence of α-32P-UTP. In vitro splicing reactions contained 20 mM Hepes pH 7.5, 44% 
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HeLa nuclear extract (prespun at 10,000 rpm for 2 minutes at 4oC), 60 mM KCl, 2.2 mM MgCl2, 
5 mM creatine phosphate, 1.5 mM ATP, 40,000 cpm pre-mRNA, and 0, 0.8, or 1.6 μM 
CUGBP2, RRM1_2, RRM2_3, or ΔDD protein in a final volume of 25 μl. Reaction mixtures were 
pre-incubated at 30oC for 10 minutes prior to the addition of pre-mRNA. Parallel splicing 
reactions were prepared in the absence of ATP, creatine phosphate, or recombinant protein as 
negative splicing controls. Note that these conditions were adjusted from the standard splicing 
reaction, which contains 2 mM MgCl2 and 44 mM KCl. It is important that the concentration of 
KCl in the HeLa nuclear extract is considered when calculating the final concentration of KCl in 
the splicing reaction. Splicing was carried out for 20-60 minutes at 30oC. Splicing was stopped 
by the addition of 25 μl proteinase K mix (10 mg/ml proteinase K, 50 mM Tris-HCl pH 7.5, 10 
mM EDTA, 10 mM NaCl, 0.2% SDS) and incubation at 30oC for an additional 10 minutes. 
Reactions were then placed on ice until all samples were ready. Samples were adjusted to 1X 
HHS (10X: 0.2 M Hepes pH 7.4, 2.5 M sodium acetate, 10 mM EDTA) and subjected to 
phenol/chloroform extraction. RNA was ethanol precipitated by the addition of 1/10 volume 3 M 
sodium acetate, 1/50 volume 10 mg/ml glycogen, and 2.5 volume 100% ethanol and incubation 
on crushed dry ice for 10 minutes followed by centrifugation at 13,000 xg for 10 minutes. RNA 
pellets were washed with 70% ethanol and resuspended in 6 μl formamide loading buffer (97% 
deionized formamide, 0.1% xylene cyanol, 0.1% bromphenol blue). Samples were heated to 
65oC for 5 minutes before half of the sample was separated on an 8% polyacrylamide 7 M urea 
gel at 400 volts for 1.5 hours. Gels were soaked in water for 1 hour (3 changes), dried 
completely under vacuum, and visualized with the BAS-2500 phosphoimaging system (Fujifilm) 
and ImageGauge software. 
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2.13 BRANCHPOINT MAPPING  
pBSDUPNI or mutant derivatives were digested with EcoRI and subjected to in vitro 
transcription without α-32P-UTP. In vitro splicing assays and recovery of splicing products and 
intermediates were carried out as described above. RNA pellets were resuspended in 5 μl 
sterile ddH2O. Branchpoints were detected by primer extension in a reaction containing 5 μl 
recovered RNA, 200 U MMLV Reverse Transcriptase (Invitrogen), 10 mM DTT, 1 mM dNTPs, 
1X First Strand Buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2), and 50 nM 5´32P-
labeled JBE5-2 primer in a total reaction volume of 20 μl. Primer and 5´-end labeling were as for 
the CMCT modification footprinting assays (section 2.6). Reactions were incubated at 37oC for 
30 minutes and were terminated by ethanol precipitation by the addition of 2.5 volumes 100% 
ethanol, 1/10 volume 3 M sodium acetate, and 1/50 volume 10 mg/ml glycogen followed by 
incubation on crushed dry ice for 10 minutes and centrifugation at 13,000 xg for 10 minutes at 
4oC. Pellets were washed with 70% ethanol and resuspended in 6 μl formamide loading buffer 
(97% deionized formamide, 0.1% xylene cyanol, 0.1% bromphenol blue). Samples were heated 
to 85oC for 2 minutes and 2 μl of the sample was separated on an 8% polyacrylamide 7M urea 
gel next to a sequencing ladder. Sequencing ladders were generated from the pBSDUPNI 
plasmid using the JBE5-2 primer and the Thermo Sequenase Cycle Sequencing Kit (USB) 
according to manufacturer’s protocol. Gels were run at 45 watts for 2 hours, dried under 
vacuum, and visualized with the BAS-2500 phosphoimaging system (Fujifilm) and ImageGauge 
software. Primer extension of Ad1 splicing intermediates and products was carried out with the 
Ad1-PE primer (5´-ACTGGAAAGACCGCGAAGAG-3´). 
 For the debranching reaction, HeLa S100 extract was pretreated with micrococcal 
nuclease by incubating 200 μl S100 extract with 1 mM CaCl2 and 6 U micrococcal nuclease for 
30 minutes at 30oC. Reactions were stopped by the addition of EGTA to a final concentration of 
 56 
4 mM. The debranching mix contained 20 mM Hepes pH 7.6, 20% glycerol, 100 mM KCl, 8 mM 
EDTA, 0.5 mM DTT, and 150 μl micrococcal nuclease-treated S100 HeLa extract in a final 
volume of 750 μl. For the debranching reaction, 5 μl RNA from the in vitro splicing reaction was 
incubated with 25 μl debranching mix at 30oC for 30 minutes. Reactions were terminated by 
proteinase K treatment, followed by phenol/chloroform extraction, ethanol precipitation, and 
primer extension as described above.  
2.14 ANALYSIS OF SPLICING COMPLEX ASSEMBLY  
Spliceosome complexes were assembled on the E5-10 wild type or mutant RNA or the Ad1 pre-
mRNA in a 10 μl reaction containing 20 mM Hepes pH 7.4, 44% HeLa nuclear extract, 2.2 mM 
MgCl2, 60 mM KCl, 1.5 mM ATP, 5 mM creatine phosphate, and 0, 1.6, or 3.2 μM CUGBP2 at 
30oC for 15 minutes. Spliceosome assembly was stopped by the addition of heparin at a final 
concentration of 2 mg/ml and incubation at 30oC for an additional 3 minutes. Half of the reaction 
was separated on a 3.75% native polyacrylamide gel (80:1 acrylamide to bis ratio) cast in 50 
mM tris-glycine buffer and run at 4 watts at 4oC for 4 hours. Gels were dried under vacuum and 
visualized with the BAS-2500 phosphoimaging system (Fujifilm) and ImageGauge software. For 
assembly of the ATP-independent E complex, the nuclear extracts were preincubated at 30oC 
for 10 minutes to deplete ATP and complexes were assembled in the absence of ATP or 
creatine phosphate for only 8 minutes.  
Oligonucleotide-directed cleavage of U1 and U2 snRNAs was carried out as described 
previously (Hoffman and Grabowski, 1992). Spliceosome assembly reactions were prepared as 
above except 1.5 U RNase H (Promega) and 400 ng antisense oligo were added to the reaction 
and the final volume was 50 μl. Samples were preincubated at 30oC for 45 minutes prior to the 
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addition of RNA for spicing complex assembly. Mock reactions lacked RNase H and antisense 
oligos. I found that mock reactions lacking exogenous RNase H but containing an antisense 
oligo still carried out snRNA cleavage because RNase H was present in the nuclear extract. For 
U1 snRNA cleavage, the P007 antisense oligo (5´-GCCAGGTAAGTAT-3´) was used and for U2 
snRNA cleavage, the P009 antisense oligo (5´-CAGATACTACACTTG-3´) was used. For 
verification of snRNA cleavage, half of the reaction was ethanol precipitated, resuspended in 10 
μl water and 6.7 μl formamide loading buffer (97% deionized formamide, 0.1% xylene cyanol, 
0.1% bromphenol blue) and separated on a 10% polyacrylamide 7 M urea gel run at 400 volts 
for 1.5 hours. Gels were soaked in ethidium bromide and visualized using the LAS-3000 
Intelligent Dark Box (Fujifilm) and Image Gauge software. 
2.15 CALCIUM PHOSPHATE TRANSFECTION AND ANALYSIS OF ENDOGENOUS 
TARGET EXONS 
HEK293T cells were grown in DMEM (Cellgro), 10% (v/v) FBS. Twenty-four hours prior to 
transfection, 2 x 105 HEK293T cells were seeded in 35 mm dishes precoated with poly-L-lysine 
(Sigma). Cells were approximately 50% confluent at the time of transfection. Before 
transfection, all reagents were brought to room temperature. For one well, 1.6 μl of 1 μg/μl 
pcDNA4/NAPOR vector or pcDNA4 His/Max vector backbone were mixed with 16.1 μl 2.5 M 
CaCl2 by vortexing briefly. Next, 65.8 μl water was added and the CaCl2-DNA mixture was 
pipetted over 83.5 μl 2X BBS, pH 7.15 (50 mM N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonic 
acid, 280 mM NaCl, 1.5 mM Na2HPO4) and vortexed for 3 seconds. The pH of the BBS solution 
should be titrated and tested every time it is prepared to optimize transfection efficiency. This 
solution can be aliquoted and stored at -20oC for future use. Mixtures were incubated at room 
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temperature for 10 minutes before 164 μl was added drop-wise to each dish. After transfection, 
cells were incubated at 3% CO2 for 36 hours prior to RNA isolation using TRIZOL reagent 
(Invitrogen). A white precipitate was visible under the microscope 24 hours after transfection. 
RT-PCR was as described for the in vivo splicing reporter assay (section 2.7) except the 
following modifications were used for PCR amplification: final primer concentration was 
increased to 2.5 μM, unlabeled primers were used, the annealing temperature was adjusted to 
55oC, and 26 cycles were carried out. A complete list of primers used for amplification of 
endogenous target exons is shown in Table 1. For amplification using the CUGBP2_E1 and 
E5/7 junction primers, 32 cycles were used. PCR samples were resolved on 2% agarose gels 
next to a 100 bp DNA ladder (Invitrogen) at 80 volts for 1-3 hours or until exon included and 
skipped bands were separated. Gel images were captured using the LAS-3000 Intelligent Dark 
Box (Fujifilm) and quantified with Image Gauge software. The profile mode was used to subtract 
background and to calculate percent exon inclusion of individual lanes. 
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 Table 1. Primers used for amplification of endogenous exons. 
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3.0  FUNCTIONAL CUGBP2 BINDING SITES ARE INTIMATELY INVOLVED IN THE 
MECHANISM OF NI EXON SILENCING 
3.1 INTRODUCTION 
The CUGBP2 splicing factor is versatile in its ability to carryout dual functions with opposite 
effects on pre-mRNA splicing. The silencing face of CUGBP2’s dual character was examined to 
determine how specific CUGBP2-nucleotide contacts alter spliceosome assembly to change the 
splicing pattern from exon inclusion to exon skipping. A general understanding of how this 
protein operates on the NI exon of the NMDA NR1 receptor will provide a framework to study 
splicing silencing of other CUGBP2 target exons and insight into the enhancing function of this 
splicing factor. This study serves as a template to study the functions of other splicing factors 
that either act solely as splicing silencers or as dual functional regulators.  
3.2 CUGBP2 BINDS TO GU-RICH MOTIFS AT THE PERIMETERS OF THE PREDICTED 
NI BRANCH SITE REGION 
A silencing role for CUGBP2 was shown for the NI exon of the GRIN1 transcript in a previous 
study but the mechanism of silencing was not characterized (Zhang et al., 2002). To gain insight 
into the mechanism, I sought to extend this analysis to identify the sequence and spatial 
arrangement of motifs associated with direct binding of CUGBP2 and silencing of the NI exon. A 
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nitrocellulose filter binding assay was used initially to locate the RNA region involved in stable 
binding by CUGBP2. Bound/total RNA was plotted as a function of increasing protein 
concentration and data were fit to a hyperbola to estimate the dissociation constants (Kd) for 
binding to individual RNA substrates. These RNA substrates included the NI exon, the NI exon 
and flanking introns, and the upstream intron, substrates E5-8, E5-10, and E5-15, respectively 
(Figure 6A). CUGBP2 was found to bind to the E5-10 and E5-15 substrates containing the 
upstream intron region with apparent dissociation constants in the nanomolar range (96 and 92 
nM Kd values), but not to the E5-8 substrate containing the exon alone (Figure 6B). Because the 
downstream intron region is not a common feature of the high affinity binding substrates, this 
region, as well as the exon, must be dispensable for high affinity binding. Note that because 
binding curves are hyperbolic and not sigmoidal, it is likely that CUGBP2 binds as a monomer or 
preformed dimer and that binding is not cooperative at the protein concentrations tested.  
 To identify the specific nucleotides contacted by CUGBP2, I next carried out chemical 
modification footprinting with the E5-10 substrate, which contains the high affinity region 
identified by filter binding. CMCT modification at the N3 position of uracil and the N1 position of 
guanine causes termination of reverse transcription initiated at a downstream primer (Brunel 
and Romby, 2000). This chemical was chosen for footprinting because of the binding preference 
of human ETR-3 for UG-rich motifs as indicated by an iterative selection procedure (Faustino 
and Cooper, 2005). A representative footprint of the region upstream from the NI exon is shown 
(Figure 6C). These results reveal that a core UGUGU and upstream flanking GU motif are 
protected by CUGBP2 in a dose-dependent manner. At high CUGBP2 concentrations (>14.4 
μM), an additional low affinity UGUG binding site was detected downstream from the core motif 
(data not shown). Regions within the NI exon and in the downstream intron were also subjected 
to RNA footprinting with CUGBP2, but no additional binding sites were detected in agreement 
with the filter binding experiments (data not shown). To verify the specificity of the assay, 
footprinting reactions were carried out with purified splicing factors U2AF and PTB. Protected  
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 Figure 6. CUGBP2 contacts GU-rich motifs in the intron upstream from the NI exon. (A) 
Schematic of the NI exon (rectangle) and flanking introns (lines) is shown with corresponding 
nucleotide lengths (numbers, top). RNA substrates (E5-8, E5-10, and E5-15) used for filter 
binding assays are indicated below. Sequence analyzed by footprinting using primer JBE5-2 
(arrow) includes the intron (lower case) and exon (uppercase) region of the 3´ splice site 
(colon). Shaded sequences represent regions protected from chemical modification by 
CUGBP2. Individual adenosines in uppercase represent predicted branchpoints. (B) 
Nitrocellulose filter binding analysis. 32P-labeled RNA substrates from (A) were assembled with 
purified recombinant CUGBP2 protein and separated into protein bound and unbound fractions. 
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Representative graphs for each RNA substrate are shown. Inset: Kd values were calculated as 
the average of three experiments; ±, standard deviation. (C) RNA footprint analysis. E5-10 RNA 
was chemically modified with CMCT in the presence or absence of purified CUGBP2 protein. 
Modified positions were detected by primer extension (lanes +CMCT), in reference to a 
sequencing ladder generated from plasmid, E5-10 (lanes T,A,C,G). Shaded rectangles at right 
represent protected regions highlighted in the sequence shown in (A). Primer extension of 
starting material without modification is shown (lane SM). 
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regions were distinct from those observed for CUGBP2 (Figure 7, lanes 1-8) and consistent with 
the known RNA binding specificities of these factors  (Singh et al., 1995).  
I next asked if CUGBP2 was binding as a monomer or dimer. To address the issue of 
stoichiometry of binding by CUGBP2 to the core and upstream motifs, I carried out a 
competition footprinting assay with CUGBP2 and PTB. CUGBP2 and PTB bind to the E5-10 
RNA substrate with similar affinities (96 and 63 nM, respectively) and the PTB binding sites 
overlap with the core but not upstream motif (Figure 7, lanes 1-4). Therefore, if CUGBP2 bound 
as a monomer to these two sites, PTB would be able to compete with CUGBP2 for binding to 
not only the core motif but also the upstream motif. This was indeed the case (Figure 7, lanes 9-
12), suggesting that one protein simultaneously contacts both of these sites. Furthermore, 
CUGBP2 binds to the rNAPORbs RNA substrate containing the core but not upstream GU motif 
with a much higher dissociation constant (456 nM) than a similar RNA containing both motifs 
(92 nM), which indicates much lower affinity binding. Therefore, flanking interaction sites are 
necessary for high affinity binding by CUGBP2.  
Taken together, these results support a model in which CUGBP2 contacts a pair of high 
affinity GU-rich motifs in the intron upstream from the NI exon. Notably, the core and flanking 
motifs protected by CUGBP2 are located at the boundaries of the predicted branch site region 
with the nucleotides protected by U2AF also within these boundaries. Thus, these results 
together with the high sequence conservation of the motifs (100%) across human, rat, mouse, 
fruit fly, and chicken genomes, support their involvement in the mechanism of silencing. 
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 Figure 7. PTB and U2AF65 bind to the polypyrimidine tract between GU-rich motifs and 
PTB can effectively compete with CUGBP2 for binding to the core and upstream motifs. 
RNA footprint analysis and sequencing ladder were carried out as in Figure 6 with the E5-10 
substrate and JBE5-2 primer. Gel, lanes 1-8: CMCT modification footprint with recombinant PTB 
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and purified HeLa U2AF. Left lane of each set, no protein; gray wedge, 1.8, 3.6, and 7.2 µM 
protein added. Shaded rectangles represent protected regions. Lanes 9-12: Competition 
footprint with recombinant PTB and CUGBP2. Left lane, no protein; right lanes, 3.6 µM 
CUGBP2; black wedge, 0, 3.6, and 7.2 µM PTB added. Shaded rectangles at right represent 
regions where CUGBP2 protection was lost by competitive binding by PTB. PTB footprint 
(UCUUCUUCU) is underlined, U2AF footprint (CUUCUU) is boxed, and CUGBP2 footprint (GU, 
UGUGU) is shaded in schematic. 
 67 
3.3 CUGBP2 MUTANTS PROVIDE INSIGHT INTO THE TOPOLOGY OF RNA BINDING 
BY INDIVIDUAL RRMS 
To learn more about the topology of binding by individual RRMs of CUGBP2, I carried out 
additional filter binding and footprinting experiments with purified recombinant CUGBP2 mutant 
proteins. These mutants included RRM1_2, RRM2_3, and ΔDD. RRM1_2 contained RRMs 1 
and 2, RRM2_3 contained RRMs 2 and 3, and ΔDD contained RRMs 1, 2, and 3. None of these 
proteins contained the divergent domain. Note that there were amino acid and charge 
differences in the linker region between RRMs 2 and 3 in the RRM2_3 and ΔDD mutants 
(RRM2_3, LE; ΔDD, SR). See Figure 4 for the predicted structure of the wild type protein and 
relative positions of RRM domains. 
 To determine the role of the divergent domain in RNA binding, I carried out RNA 
footprinting with the ΔDD mutant. This mutant protected the same nucleotides as the wild type 
protein, indicating that the divergent domain is dispensable for intimate protein-nucleotide 
interactions (Figure 8, lanes ΔDD). Perhaps one role of the divergent domain is to position 
RRMs relative to each other to provide flexibility in binding to flanking interaction sites separated 
by various distances. In support of this, ΔDD bound to the shorter rNAPORbs RNA (containing 
only the core motif) better than the wild type protein but not as well to the longer E5-10 and E5-
15 RNA substrates (containing both motifs) (Table 2). RRM2_3 protected the same nucleotides 
as the wild type protein (Figure 8, lanes RRM2_3) and bound to the rNAPORbs RNA substrate 
with highly similar affinity (Table 2). Therefore, it seems that RRM1 and the divergent domain 
are dispensable for high affinity protein-nucleotide interactions.  
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 Figure 8. CUGBP2 RRMs 2 and 3 are sufficient for protection of the core and upstream 
GU-rich motifs. CMCT modification footprint analysis was carried out as in Figure 6 with 
protein concentrations ranging from 0 to 14.4 μM as indicated above the gel. Shaded rectangles 
represent protected regions. Primer extension of starting material without modification is shown 
(SM). Protected nucleotides are indicated on the sequence below the gel. Regions protected by 
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CUGBP2, RRM2_3, and ΔDD are shaded and regions protected by RRM1_2 are boxed. Arrow 
indicates the location of the JBE5-2 primer used for primer extension of modified RNA. 
Sequencing ladder was generated from plasmid, E5-10 (lanes T,A,C,G), using the JBE5-2 
primer. 
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RRM1_2 bound to the E5-10 and E5-15 RNA substrates with approximately five times 
less affinity than the wild type protein (Table 2). In the footprinting assay, this mutant only 
contacted a UGU from the core and GU from the upstream motif, but not to a complete set of 
motifs (Figure 8, lanes RRM1_2). Therefore, RRMs 1 and 2 are insufficient for high affinity 
binding and proper nucleotide protection. RRM2 may be involved in stable binding to the shorter 
upstream motif and may contact part of the core motif when binding in an alternate register.  
 
    Table 2. Summary of nitrocellulose filter binding assays. 
 
 
Taken together, these data support a model in which RRM2 contacts the upstream motif 
and RRM3 contacts the core motif with the divergent domain providing flexibility in the 
positioning of RRMs 2 and 3 relative to each other (Figure 9). The divergent domain and RRM1 
are dispensable for high affinity binding and may be involved in protein-protein interactions or 
nuclear localization (Ladd and Cooper, 2004; Goo and Cooper, 2009). Additionally, CUGBP2 
may bind in an alternate register of less affinity by contacting a GU at the core motif and UGUG 
at the downstream motif. Still, these results do not rule out binding by CUGBP2 as a monomer 
to all three motifs nor can I confirm that individual RRMs function properly when taken out of the 
wild type context. Structural studies are necessary to fully understand the topology of binding. 
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 Figure 9. Model of the proposed topology of RNA binding by CUGBP2. Relative positions 
of GU-rich motifs are shown on the intronic RNA sequence (curved line) in the 5´ to 3´ direction. 
CUGBP2 (dark blue) binds with highest affinity to the upstream GU and core UGUGU motif with 
RRM2 (2) contacting the upstream GU and RRM3 (3) contacting the core UGUGU motif. 
CUGBP2 (light blue) also binds with less affinity to a GU at the core motif and a UGUG at the 
downstream motif. The divergent domain (DD) and RRM1 (1) are not necessary for protection in 
the footprinting assays and may mediate CUGBP2 protein-protein interactions or nuclear 
localization. The divergent domain functions to correctly position RRMs 2 and 3 relative to each 
other. 
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3.4 CUGBP2 BINDING SITES ARE NECESSARY, SUFFICIENT, AND SPECIFIC FOR 
EXON SILENCING 
In order to determine whether nucleotides in contact with CUGBP2 upstream from the NI exon 
are necessary for its silencing role, I generated an in vivo splicing reporter with the NI exon and 
its immediate adjacent flanking introns inserted between β globin exons 1 and 2 (DUPNIwt) 
(Figure 10A). Mutant derivatives of this reporter contained site-directed mutations in the GU 
dinucleotide and UGUGU core motifs (m1 and m2 motifs, respectively) as identified by 
footprinting. A nearby UGUG motif (m3) was also mutated, since it showed weak protection in 
the footprinting assays.  
Splicing reporters were co-expressed in the presence and absence of CUGBP2 in 
C2C12 mouse myoblast cells or N18TG2 mouse neuroblastoma cells, which have little or no 
endogenous protein as shown by Western blotting (Figure 11). The change in exon inclusion 
value, ΔEI, was then calculated as the difference between the % exon inclusion ± CUGBP2. The 
ΔEI value is used here as a convenient measure of the effectiveness of CUGBP2 to induce 
exon skipping (or silencing). While CUGBP2 expression in C2C12 cells induced exon skipping 
of the wild type substrate with a ΔEI value of –33% (Figure 10B, lanes wt) mutations in all three 
motifs eliminated silencing entirely as indicated by a ΔEI value of 0% (lanes m1,2,3). The double 
mutations also showed a significant reduction in the silencing effect of CUGBP2 (lanes m1,2, 
m2,3, m1,3). Of this group, combined mutations at positions m1 and m2 showed the smallest 
degree of silencing (ΔEI -5%), suggesting that these sites are intimately involved in the 
mechanism of action. Single mutations also showed a reduction in silencing indicative of 
additive effects (lanes m1, m2, m3). Similar results were observed in N18TG2 cells with 
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 Figure 10. The UGUGU core motif and flanking GU dinucleotides are functionally 
important for CUGBP2 silencing. (A) Schematic of wild type (wt) and mutant versions of the 
DUPNI splicing reporter. The NI cassette exon (shaded rectangle) and regions of the native 
flanking introns (shaded lines) were inserted between β-globin exons βE1 and βE2 downstream 
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of a CMV promoter. Nucleotide lengths in base pairs are indicated above and below schematic. 
Sequence shows an expanded view of the NI 3´ splice site region with mutations m1, m2, and 
m3 indicated by underscores below the shaded regions. Arrows indicate the location of primers 
used for RT-PCR amplification of exon included and exon skipped mRNAs. (B) Splicing reporter 
analysis in C2C12 cells. Splicing reporters with no mutation (wt), with single (m1, m2, m3), or 
combined (m1,2, m2,3, m1,3, m1,2,3) mutations were expressed with vector backbone control  
(-) or with pcDNA4/CUGBP2 expression vector (+). The gel panel is a representative 
polyacrylamide gel image with the top band corresponding to the exon included and the bottom 
band corresponding the exon skipped mRNA. The bar graph shows the percent exon inclusion 
as an average of three separate experiments. The change in percent exon inclusion (ΔEI) as a 
function of CUGBP2 expression is shown below the gel panel. Inset: Western blot analysis was 
used to verify Xpress-tagged CUGBP2 expression; endogenous hnRNPA1 was a loading 
control. (C) Experiments were as in (B) except N18TG2 cells were used. 
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 Figure 11. Quantitative Western blot analysis of whole cell lysates demonstrates that 
endogenous CUGBP2 levels are low in C2C12 and N18TG2 cells. Whole cell lysates (WCL) 
were obtained from 90% confluent 10 cm dishes of each cell type as indicated (top right). 
Twenty-five or 50 μl of cell lysate was loaded and Western blotting was carried out with 
αCUGBP2 (1H2), αCUGBP1/2 (3B1), or αhnRNPA1 (9H10) antibodies as indicated at right. Left 
panel is Western blot analysis of recombinant CUGBP2 as a control for antibody sensitivity and 
relative protein levels. αhnRNPA1, loading control. 
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consistent loss of silencing by CUGBP2 with each mutation (Figure 10C). New to this cell type is 
higher basal levels of inclusion in the absence of CUGBP2 and reduced silencing by CUGBP2 
on all substrates tested. This could be the consequence of the differential expression of splicing 
factors in these two cell lines. That is, an enhancer may act on the NI exon in N18TG2 cells and 
may be better able to compete with CUGBP2 when its binding sites are compromised. A good 
candidate enhancer is Fox because a perfect match to its enhancer element, (U)GCAUG 
(Auweter et al., 2006), is located near the NI 5´ splice site in the downstream intron. 
I also demonstrate that the m1, m2, and m3 motifs are involved in tissue-specific 
silencing of the NI exon in the context of the DUPNI splicing reporter in transfected primary 
cortical cultures (Figure 12A). It is important to note that I did not overexpress CUGBP2 in the 
primary cultures, therefore reporter splicing patterns are a result of endogenous splicing factors 
acting on pre-mRNA from transfected plasmids. The NI exon is only included 50% of the time 
when all three motifs are intact (lanes DUPNI) as compared to 95% of the time when the m1 
and m2 motifs are mutated (lanes m1,2 and m1,2,3). Furthermore, individual and combinations 
of mutations confirm additive effects in primary cultures (lanes m1, m2, m3, m2,3, and m1,3). I 
verify nuclear expression of CUGBP2 in primary cortical cultures by Western blotting (Figure 
12B) and show that CUGBP2 is expressed in both neurons and glial cells by 
immunofluorescence (Figure 12C). DAPI nucleic acid stain was used to verify nuclear 
localization in both neurons and glial cells (data not shown). Taken together, CUGBP2 is 
expressed in the nucleus of cortical neurons where it likely regulates NI exon splicing through 
the m1, m2, and m3 motifs.  
To further investigate the roles of the m1, m2, and m3 motifs for exon silencing by 
CUGBP2, I introduced a 39 nucleotide region containing the three motifs upstream of a 
constitutive exon in a different context (Figure 13A). Constitutive exon 3 of the DIP13β transcript 
was tested, since its splicing pattern is insensitive to CUGBP2 regulation, and unlike the NI  
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 Figure 12. NI exon skipping in primary cortical cultures depends on the m1, m2, and m3 
motifs and correlates with CUGBP2 expression. (A) In vivo splicing reporter analysis. 
DUPNIwt (DUPNI) and mutant (m1, m2, m3, m1,2, m2,3, m1,3, m1,2,3) splicing reporters were 
transfected into rat primary cortical neurons for 24 hours prior to RNA isolation and RT-PCR 
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analysis. The gel panel is a representative polyacrylamide gel image with the top band 
corresponding to the exon included and the bottom band corresponding the exon skipped 
mRNA. The bar graph shows the percent exon inclusion as an average of two separate 
experiments. (B) Western blot analysis of nuclear lysates with αCUGBP2 (1H2) and 
αCUGBP1/2 (3B1) antibodies shows endogenous CUGBP2 expression in rat primary cortical 
cultures. Two and a half, 5, or 10 μl nuclear lysate was loaded as indicated at top. αhnRNPA1 
was used as a loading control. (C) Immunofluorescence analysis demonstrates that CUGBP2 is 
enriched in the nucleus and soma of rat primary cortical neurons and glial cells. Mixed cultures 
of neurons and glial cells were grown on coverslips and assayed for cell type-specific CUGBP2 
expression (αCUGBP2) by costaining with a neural (Neurofilament L) or glial (GFAP) cell-
specific antibody. An overlap of confocal images is shown at right. 
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 Figure 13. CUGBP2 silencing motifs are functionally transferable. (A) A 39 nucleotide 
region containing the m1, m2, and m3 silencing motifs from the NI intron was inserted upstream 
from DIP13β exon 3 (middle exon) in the SIRT1 splicing reporter context (DIPNIwt). Expression 
was driven by the SV40 promoter. Nucleotide lengths in base pairs are indicated. Arrows 
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indicate primers used for RT-PCR amplification; numbers below give nucleotide lengths 
contributing to PCR products. Individual or combinations of mutations were introduced at 
CUGBP2 regulatory sites as in Figure 10. Sequence of control region (DIPm93wt) corresponds 
to 3´ splice site region of constitutive exon, DIP13β exon 3. (B) Splicing reporter plasmids 
(m93wt, NIwt, m1, m2, m3, m1,2, m2,3, m1,3, m1,2,3) were cotransfected in C2C12 cells with 
vector backbone control (-) or with pcDNA4/CUGBP2 expression vector (+). The graph, gel 
image, and ΔEI calculation are as described for Figure 10. (C) Experiments were as in (B) 
except N18TG2 cells were used. 
 81 
exon is not under alternative splicing control. The introduction of the 39 nucleotide region 
conferred strong silencing by CUGBP2 (Figure 13B, lanes NIwt; ΔEI, -54%), in contrast to the  
parent plasmid, which was unregulated by CUGBP2 (lanes m93wt; ΔEI, ~0%). Single and 
combined mutations in the m1, m2, and m3 motifs were also tested in this context (lanes m1, 
m2, m3, m1,2, m2,3, m1,3, and m1,2,3). Exon silencing by CUGBP2 was nearly eliminated 
when site-directed mutations were introduced into both the m1 and m2 motifs (lanes m1,2; ΔEI, 
-6%). Mutations in both the m2 and m3 motifs also led to a significant reduction in silencing 
(lanes m2,3). Thus, the general requirement for a pair of proximal CUGBP2 motifs, and the 
additive effects of the single mutations were verified in this context. This heterologous reporter 
was also tested in N18TG2 cells (Figure 13C). In this context, results were consistent between 
cell lines. Furthermore, compared to the NI exon, DIP13β E3 has strong 5´ and 3´ splice sites 
and individual mutations have less of an effect on the basal level of inclusion. Therefore, this 
reporter is a good system to study isolated effects of CUGBP2 on the m1, m2, and m3 motifs. 
I also tested the silencing role of a closely related family member, CUGBP1, on wild type 
and mutant substrates since it is expressed in both cell lines tested (Figure 11). CUGBP1 
silences the NI exon (Figure 14A, lanes DUPNI wt) with a dependence on the same motifs 
(lanes DUPNI m1,2,3). However, CUGBP1 silencing is much weaker in the DIPNI context (lanes 
DIPNI wt, ΔEI -16 compared to ΔEI -54 for CUGBP2) indicating that additional sites outside of 
the transferred region are necessary for strong silencing by CUGBP1. In support of this, exon 3 
of the DIPNIwt reporter is included >99% of the time in N18TG2 cells (Figure 13C, lanes NIwt) 
despite high levels of endogenous CUGBP1 (Figure 11). Therefore, CUGBP1 shows a weaker 
silencing role compared to CUGBP2 and splicing effects from endogenous CUGBP1 should not 
interfere with CUGBP2 overexpression studies. As additional controls, I carried out similar 
experiments with overexpression of PTB or Nova, since both of these factors are known to 
silence the NI exon through distinct motifs (UCUU and YCAY, respectively; Y, pyrimidine)  
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 Figure 14. CUGBP2 regulatory motifs are specific. (A) Splicing reporters (top) were 
transfected into C2C12 cells in the presence (+) or absence (-) of CUGBP1 as indicated and 
included and skipped forms of spliced reporter RNA were assayed by RT-PCR and separated 
on a polyacrylamide gel. Gel image is representative of three separate experiments. Percent 
exon inclusion (EI (%)) and the change in percent exon inclusion (ΔEI (%)) with CUGBP1 
overexpression is indicated below the gel panel. ≠The effect of CUGBP2 overexpression is 
shown for comparison. (B) Splicing reporter assays were carried out as in (A) except Nova and 
PTB protein expression vectors were used. VBB, vector backbone control. 
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(Zhang et al., 1999). As expected, PTB and Nova were active in silencing the NI exon in the 
context of the DUPNIwt splicing reporter, and these effects were maintained in the presence of 
the m1,2,3 triple mutation (Figure 14B). Furthermore, the region transferred to the DIPNIwt 
splicing reporter was insufficient for strong splicing silencing by Nova or PTB. Thus, the m1, m2, 
and m3 motifs are specific for silencing by CUGBP2. 
3.5 CUGBP2 BLOCKS BRANCHPOINT FORMATION BETWEEN GU-RICH MOTIFS 
I hypothesized that CUGBP2 may function to silence the NI exon by blocking branchpoint 
formation in the upstream intron. Based on complementarity to U2 snRNA, two candidate 
branch sites, A1 and A2, are located between the m1 and m2 motifs, and a third, weaker 
candidate, A3, resides just downstream between the m2 and m3 motifs (Figure 15A). As a test 
of this hypothesis, I measured branchpoint formation for the DUPNI substrate under in vitro 
splicing conditions in the presence and absence of recombinant CUGBP2. Note that 
endogenous CUGBP2 levels are not detectable in HeLa nuclear extracts by immunoblotting with 
the 1H2 antibody, which is highly specific for CUGBP2 (Ladd et al., 2005). According to the 
perimeter-binding model, the addition of recombinant CUGBP2 to the extract should bind and 
preferentially occupy motifs m1 and m2 on the wild type substrate with the resulting inhibition of 
one or more of the branch sites in this neighborhood. The protein can also bind in an alternate 
register of lower affinity by contacting a GU at the m2 site and UGUG at the m3 site. Alternately, 
one protein may contact all three sites simultaneously.   
Branchpoints were detected by primer extension as for the experiments in Figure 6C. 
The results for the wild type substrate verified the use of the predicted branchpoints with a 
preference for A1 and A2, compared to A3 (Figure 15B, lanes 2,3). The A1 and A2 branchpoints 
satisfied the criteria for ATP dependence (lane 1). Primer extension of reactions following  
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 Figure 15. CUGBP2 blocks branchpoint formation between RNA-protein contact sites. (A) 
Schematic of the DUPNI pre-mRNA used for in vitro splicing assays. The NI exon and adjacent 
intron regions are shaded; numbers above schematic indicate nucleotide sizes. Expanded 
region shows perimeter-binding model with relative positions of CUGBP2 motifs (m1, m2, m3) 
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and branchpoint adenosines (A1, A2, A3) mapped in these experiments. Branch site sequences 
are shown at right; branchpoint adenosine, asterisk; nucleotides matching the consensus, 
YUNAY (Y, pyrimidine; N, any nucleotide), uppercase; mismatches, lowercase. (B) Gel panels 
show primer extension analysis of splicing intermediates of the wild type (wt), m1, m3, and 
m1,2,3 DUPNI RNA substrates (bottom) with primer, JBE5-2. Schematic at right illustrates the 
termination of reverse transcriptase at branchpoint positions in the assay. Branchpoint numbers 
on gel correspond to positions indicated on sequence in (A). A sequencing ladder is shown for 
the pBSDUPNI plasmid (ladder). For lanes 1-12, splicing reactions containing ATP (+ATP 
lanes) were incubated for 45 and 60 min with (+) or without (-) 1.6 μM recombinant CUGBP2. 
Control reactions lacked ATP. For lanes 13-18, 60 min splicing reactions were used. Boxes 
emphasize the inhibition of branchpoints A1 and A2 on the wild type substrate but not on the 
m1,2,3 mutant RNA substrate. 
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debranching showed a loss of stops at A1, A2, and A3 providing confirmation that all three of 
these adenosines are used as branchpoints (Figure 16). Notably, branchpoint formation was 
inhibited when the in vitro splicing reactions were supplemented with recombinant CUGBP2 
(Figure 15B, lane 4). An analysis of the corresponding in vitro splicing reactions confirmed that 
CUGBP2 inhibited the formation of splicing intermediates of these reactions (Figure 17, lanes 
wt). Note that I also carried out the in vitro splicing reactions in the presence of a PTB 
competitor because PTB levels are artificially high in HeLa nuclear extract and PTB has been 
shown to inhibit splicing of the NI exon (Zhang et al., 1999; Zhang et al., 2002). However, I did 
not observe a significant difference in splicing or CUGBP2 regulation in the presence of the PTB 
competitor under all conditions tested (data not shown). 
I next examined the effect of the single mutation in motif m1 as a test of whether 
branchpoint inhibition occurs between core and flanking motifs. That is, a single mutation in m1 
should permit the binding of CUGBP2 to the remaining intact sites (m2 and m3) leading to 
preferential inhibition of branchpoint A3. Indeed, under conditions in which the m1 site was 
mutated, branchpoint A3 was preferentially inhibited as expected for a model involving flanking 
interaction motifs (Figure 15B, lanes 7,8). Consistent with this observation, the corresponding in 
vitro splicing gel showed that CUGBP2 inhibited the formation of one lariat intermediate but not 
the other (Figure 17, lanes m1). For the single mutant, m3, which should display the reciprocal 
pattern of inhibition by CUGBP2, branchpoints A1 and A2 were preferentially inhibited relative to 
A3 (Figure 15B, lanes 11,12). Finally, the triple mutant, m1,2,3, was tested. Here, the 
elimination of all three binding motifs neutralized the inhibitory effects of CUGBP2 on 
branchpoint formation (lanes 17,18). Again, these results were consistent with the splicing 
intermediates of these reactions (Figure 17, lanes m3 and m1,2,3). Adenovirus major late (Ad1) 
pre-mRNA was tested as a control, because Ad1 pre-mRNA lacks CUGBP2 motifs in the 
upstream intron. Both the in vitro splicing and branchpoint formation of Ad1 were unaffected by 
the addition of recombinant CUGBP2 (Figure 18A/B). Under in vitro splicing conditions tested, it 
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 Figure 16. Three branchpoints in the intron upstream from the NI exon were confirmed 
with a debranching control. Branchpoint analysis of the DUPNI pre-mRNA was carried out as 
in Figure 15 with (+) or without (-) debranching prior to primer extension. Branchpoint numbers 
correspond to numbers in Figure 15. Schematics at right illustrate the termination of reverse 
transcription on various RNA intermediates and products. Asterisks mark unidentified bands that 
may represent different transcription start sites or the use of cryptic splice sites. Sequencing 
ladder generated from the pBSDUPNI plasmid is shown, Ladder. 
 88 
 Figure 17. Recombinant CUGBP2 inhibits splicing of the intron upstream of the NI exon 
in vitro. In vitro splicing reactions were carried out using the two exon pre-mRNAs, DUPNI wild 
type (wt) and mutant derivatives m1, m3, and m1,2,3 (top). The presence (+) or absence (-) of 
ATP or 1.6 μM recombinant CUGBP2 and the time of incubation are indicated at the top of the 
gel. The structures of RNA intermediates and products are indicated at right. Note that the time 
dependence of the accumulation of branchpoints mapped in Figure 15 coincides with the 
appearance of the intron lariat-3´ exon intermediate. The doublet band in the vicinity of the 
intron lariat is consistent with branchpoints at varying distances from the 3´ splice site (see for 
example, lane 6 from left). 
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 Figure 18. Ad1 pre-mRNA is resistant to splicing silencing by CUGBP2. (A) In vitro splicing 
reactions were carried out with the Ad1 two exon pre-mRNA in the presence (+) or absence (-) 
of ATP or 1.6 μM recombinant CUGBP2 protein for 20 or 40 minutes as indicated at the top of 
the gel. RNA intermediates are shown at right. (B) Branchpoint analysis of Ad1 pre-mRNA was 
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carried out in the presence (+) or absence (-) of ATP or 1.6 μM recombinant CUGBP2. Splicing 
reactions were carried out for 20 or 40 minutes as indicated above the gel. Asterisk, position of 
branchpoint mapped in these experiments. Right, debranching reaction of the branchpoint 
detected after 20 minutes in the presence of ATP without CUGBP2. (C) Analysis of splicing 
complex assembly on the Ad1 substrate in the presence (+) or absence (-) of ATP, 1.6 μM 
recombinant CUGBP2, or U2 snRNA cleavage. Location of complexes E, A, B, and C are 
shown at left. (D) Schematic of Ad1 pre-mRNA with the L1 and L2 exons (rectangles) and intron 
regions (lines) shown. Sizes in nucleotides are indicated above the schematic and the sequence 
of the 3´ splice site region is shown below with the branch site region underlined and the 
branchpoint adenosine indicated with a capital A. 
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seems that CUGBP2 has a stabilizing effect on the nuclear extract and actually appears to 
enhance Ad1 splicing. 
To provide support for the RNA binding model in Figure 9, I asked if the RRM2_3 mutant 
was capable of blocking branchpoint formation and in vitro splicing of the DUPNI pre-mRNA. 
Both branchpoint formation (Figure 19A, lanes RRM2_3) and in vitro splicing reactions (Figure 
19B, lanes RRM2_3) were inhibited by the addition of recombinant RRM2_3 to the nuclear 
extract. Furthermore, the RRM1_2 mutant was insufficient for branchpoint (Figure 19A, lanes 
RRM1_2) or in vitro splicing (Figure 19B, lanes RRM1_2) inhibition, consistent with a model 
involving branchpoint inhibition by physical occlusion of the branch site region by binding to 
flanking interaction sites.  
Surprisingly, the ΔDD mutant activated branchpoint formation (Figure 19A, lanes ΔDD) 
and in vitro splicing (Figure 19B, lanes ΔDD) of the DUPNI pre-mRNA. A possible explanation 
for this is that in the absence of the divergent domain, RRM1 may interact with enhancing 
factors to activate splicing. Additionally, differences in the charge between RRMs 2 and 3 in the 
RRM2_3 (negative) and ΔDD (positive) mutants may contribute to the different functions of 
these proteins (RRM2_3 silences and ΔDD enhances). In the future, it would be interesting to 
investigate the role of RRM1 in splicing enhancement or the effects of charge differences in the 
divergent domain on protein function. 
Note that the DUPNI two-exon substrate used in these reactions contained the NI exon 
and upstream exon. The RNA substrate containing the NI exon and downstream exon did not 
splice in vitro, probably because of a weak 5´ splice site at the NI exon. Therefore, it is likely that 
splicing of the upstream intron activates splicing of the downstream intron. If NI splicing naturally 
occurs in this order, it makes sense that CUGBP2 inhibits the first step. 
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 Figure 19. RRMs 2 and 3 are sufficient for branchpoint inhibition. (A) CUGBP2 mutants 
have differential effects on branchpoint formation on the DUPNI pre-mRNA substrate. In vitro 
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splicing was carried out for 60 minutes in the presence (+) or absence (-) of ATP and 0.8 or 1.6 
μM recombinant CUGBP2 mutant proteins (wedge) as indicated above the gel. Branchpoints 
were detected by primer extension with the JBE5-2 primer as indicated by the schematic at 
right. Branchpoints in the gel are numbered as in Figure 15. A sequencing ladder generated 
from the pBSDUPNI plasmid with the JBE5-2 primer is shown for reference (lanes T,A,G,C). (B) 
CUGBP2 mutants have differential effects on in vitro splicing of the DUPNI pre-mRNA 
substrate. In vitro splicing was carried out for 60 minutes in the presence (+) or absence (-) of 
ATP or recombinant CUGBP2 mutant proteins, RRM1_2, RRM2_3, or ΔDD, as indicated above 
the gel. Wedge indicates 0.8 and 1.6 μM protein. Splicing intermediates and products are 
labeled at right. Below the gel, % splicing is indicated as the intensity of the lariat 3´-exon 
intermediate band normalized to unspliced pre-mRNA for each lane. 
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3.6  CUGBP2 INHIBITS COMPLEX A FORMATION AND U2 snRNP BINDING 
To determine what step before branchpoint formation is specifically affected by the addition of 
CUGBP2 to the splicing reaction, I analyzed complex assembly on the E5-10 RNA substrate in 
the presence or absence of recombinant CUGBP2. I confirmed that CUGBP2 blocks U2 snRNP 
association because CUGBP2 inhibited complex A formation on the wild type substrate but not 
on the triple mutant substrate (Figure 20A). I verified that the complex was complex A and 
involved U2 snRNP because it did not form upon U2 snRNA cleavage (Figure 20A/B). In 
contrast, parallel samples assembled in the absence of ATP showed no effect of CUGBP2 on 
complex E (Figure 20C). I also carried out splicing complex formation on the Ad1 pre-mRNA in 
the presence and absence of recombinant CUGBP2 as a negative control (Figure 18C). Here, 
Ad1 splicing complex formation was resistant to CUGBP2. 
The results shown above are consistent with a model in which site-specific binding of 
CUGBP2 surrounding the branch site region mediates exon skipping. Because exon definition 
could potentially affect branchpoint formation in the upstream intron by interactions involving U1 
snRNP and U2AF across the exon, I asked whether strengthening the 5´ splice site of the NI 
exon would antagonize the silencing effect of CUGBP2.  For this purpose, I increased the 
complementarity of the 5´ splice site to U1 snRNP and tested the ability of CUGBP2 to induce 
silencing in vivo. This mutation had no detectable effect on silencing by CUGBP2 (Figure 21). I 
also show that U2AF and CUGBP2 can contact the same RNA at the same time indicating that 
branchpoint inhibition occurs after U2AF but before U2 snRNP binding (Figure 22). This, 
together with the lack of effect of CUGBP2 on complex E, which contains U1 snRNP, U2AF, 
and SF1, is consistent with a mechanism involving inhibition at a step subsequent to exon  
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 Figure 20. Recombinant CUGBP2 inhibits U2 snRNP binding and complex A but not 
complex E formation. (A) CUGBP2 inhibits complex A formation and U2 snRNP binding. 
Splicing complex formation was carried out in the presence (+) or absence (-) of ATP, 1.6 (+) or 
3.2 (++) μM CUGBP2, or U2 snRNA cleavage as indicated at top on either wild type (wt) or 
triple mutant (m1,2,3) E5-10 RNA substrates as indicated below for 15 minutes at 30oC. The 
position of the ATP-independent complexes E and H are shown at left and the ATP-dependent 
complex A is shown at right. (B) Conformation of oligonucleotide-directed cleavage of U1 and 
U2 snRNA (indicated at top). Positions of uncleaved U1 and U2 snRNA are shown at left. (C) 
CUGBP2 does not inhibit complex E formation. Splicing complex formation was carried out as in 
(A) except ATP was omitted and reactions were incubated for only 8 minutes. U1 snRNA 
cleavage is shown to confirm the identity of the U1 snRNP containing complex E. (D) Model for 
splicing complex assembly on the E5-10 wild type RNA substrate in the presence of CUGBP2. 
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 Figure 21. Strengthening the NI exon 5´ splice site complementarity to U1 snRNP does 
not affect splicing silencing by CUGBP2. (A) Schematic of mutations made to the 5´ splice 
site of the DUPNIwt splicing reporter to strengthen U1 snRNP binding (DUPNI5´ssAG, shaded 
nucleotides). Schematic is as described in Figure 10. (B) In vivo splicing reporter assay with co-
expression of a vector backbone control (vbb) or CUGBP2 protein and the DUPNIwt or 
DUPNI5´ssAG splicing reporter as indicated at top. Gel, bar graph, and ΔEI calculation are as in 
Figure 10. 
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 Figure 22. CUGBP2 and U2AF can bind to the same RNA at the same time. Increasing 
amounts of recombinant wild type or mutant CUGBP2 were bound to E5-10 RNA in the 
presence or absence of HeLa purified U2AF. Protein concentrations are labeled on the top of 
the gel and free RNA and RNA-protein complexes are labeled at right. U2AF binding alone to 
the E5-10 RNA substrate is shown for comparison (last three lanes at right). 
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definition. Thus, the inhibitory role of CUGBP2 is likely to involve direct antagonism of U2 
snRNP binding at the NI branch site region. 
3.7 DISCUSSION 
In this study, I reveal a novel mode of exon silencing by the CUGBP2 splicing factor. I clearly 
demonstrate that CUGBP2 binds to an arrangement of functional GU-rich motifs at the 
perimeters of the NI branch site region. I show that by binding to flanking interaction sites, 
CUGBP2 inhibits branchpoint formation and splicing at the upstream intron. I provide additional 
support for a model involving direct branchpoint inhibition by demonstrating that CUGBP2 
inhibits U2 snRNP association but has no effect on exon definition events. Taken together, I 
conclude that the silencing face of the CUGBP2 splicing factor silences an ensemble of 
branchpoints from flanking interaction sites to cause skipping of the NI exon. This study 
underscores the importance of the branch site region in alternative splicing regulation and 
provides a framework to study splicing regulation of the CI cassette and other CUGBP2 target 
exons throughout the transcriptome.  
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4.0  A PREDICTIVE CODE FOR CUGBP2 REGULATION WITH IMPLICATIONS FOR 
AUTOREGULATION 
4.1 INTRODUCTION 
The CUGBP2 splicing factor is highly enriched in the brain where it regulates alternative splicing 
and has a general impact on cognitive brain function (Philips et al., 1998). However, only a few 
CUGBP2 target exons have been identified. Therefore, I wanted to identify a code for splicing 
silencing that could be applied to additional CUGBP2 target exons. Regulation of predicted 
target exons would provide general support for the branch site-perimeter-binding model and will 
be useful in understanding the complete network of exons that are regulated by CUGBP2.  
4.2 PREDICTION, IDENTIFICATION, AND CHARACTERIZATION OF CUGBP2 TARGET 
EXONS 
A recent publication by Yeo, et al. (2007) used computational approaches to identify intronic 
splicing regulatory elements (ISREs) in the introns upstream and downstream from skipped 
exons (Yeo et al., 2007). One of the ISREs identified was a UGUGUU motif with the propensity 
to be found within 400 nucleotides of conserved skipped exons. The Yeo study identified 168 
skipped exons with a UGUGUU motif in their upstream intron. I obtained this list for further 
analysis. 
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In order to extend this analysis to identify additional exons that are potentially silenced 
by CUGBP2, I searched the list of 168 exons for the following sequence features: (1) the 
presence of conserved pairs of UGUGU and GU motifs within 100 nucleotides of the 3´ splice 
site of the skipped exon with a spacing of 10-30 nucleotides between the motifs, and (2) the 
presence of potential branch site(s) between the motifs. Because the m1 and m2 motifs are 
sufficient to inhibit branchpoints A1 and A2 on the DUPNI substrate, I rationalized that two 
motifs flanking the branch site would be sufficient to predict CUGBP2 regulation. Potential 
branch sites were required to match the human consensus sequence, YUNAY (Y, pyrimidine; N, 
any nucleotide) with one mismatch allowed (Gao et al., 2008). From this analysis I determined 
that 48 of the 168 exons (29%) fit these criteria. I chose 27 exons to test for regulation by 
CUGBP2. Sequence features of regulated exons and controls are shown in Figure 23.  
To analyze the response of these endogenous exons to CUGBP2 overexpression, I 
optimized a calcium phosphate transfection method to obtain >90% transfection efficiency in 
HEK293T cells. HEK293T cells were chosen for these experiments, since there is no detectable 
expression of CUGBP2 (Figure 24A, Western blot). RNA was harvested from the cells and the 
test exon region was amplified by RT-PCR with primers specific for the flanking exons. Ten 
predicted exons showed an increase in exon skipping when CUGBP2 was overexpressed 
(Figure 24A, panels MAP4_E15, SORBS1_E5, PPF1BP1_E19, SMARCE1_E4, FOX2_E11, 
CUGBP2_E6, NFAT_E2, CTBP1_E2, PTER_E3, and MLLT10_E13). Of the 17 exons that were 
not affected by CUGBP2, one was constitutively included and resistant to CUGBP2 
(NDRG3_E3), 8 were not expressed in HEK293T cells (HNT_E7a, MED15_E5, SEC14L4_E8, 
RGS7_17a, KCNMA_E19a, SCUBE1_E6a, CKLF_E3, DYNC1I1_E5), and 8 were always 
skipped, therefore, CUGBP2 could not induce additional skipping (MYO9A_E26a, PLCH1_E21, 
SRPK2_E14a, CTNND1_E16, BNIP2_E4a, AFAP1_E13, BBX_E3a, ATP6VOA1_E19). Taken 
together, 10 out of 11 testable exons were regulated by CUGBP2 indicating that I have 
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 Figure 23. Prediction of additional CUGBP2 target exons. Model depicting the inhibition of 
branchpoint formation by the binding of CUGBP2 to flanking interaction sites. Below schematic: 
For all predicted target exons, the gene name and exon number are labeled and the predicted 
branch sites between GU-rich motifs are shown. Branchpoint adenosine (A*); lowercase letters 
indicate mismatches to the branch site consensus. Spacing in nucleotides (nt) between the 
perimeter motifs is shown for all tested exons. 
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 Figure 24. A motif code for splicing silencing reveals novel endogenous exons that are 
silenced by CUGBP2. (A) HEK293T cells were transfected for 36 hours with CUGBP2 protein 
expression vector (CUGBP2) or vector backbone control (vbb) prior to RNA isolation and RT-
PCR analysis of endogenous target exons. Exon included (*) and skipped (**) RT-PCR products 
are shown after separation on 2% agarose gels. The gene name and exon number are labeled 
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above each panel. Note that relative band locations are not shown to scale. For MLLT10, 
primers are specific for exons 12 and 15 with alternatively spliced exons 13 and 14 in between. 
Splicing of exon 14 is resistant to CUGBP2. Note that included and skipped bands are 
designated as exon 13 included and skipped. Inset: Western blot analysis confirming CUGBP2 
expression (αXpress); total CUGBP2 as detected by 1H2 antibody (αCUGBP2), CUGBP1 and 2 
using 3B1 antibody (αCUGBP1,2), and loading control (αhnRNPA1). (B) Black box: RT-PCR 
detection of the E5/E7 junction (jxn) of the endogenous CUGBP2 transcript with overexpression 
of CUGBP2. Right, the E1/jxn primer set cannot amplify the CUGBP2 protein expression vector 
but the E5/E7 primer set can. Lane L, 100 bp ladder. 
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identified a specific code that can be used to accurately predict CUGBP2 regulation. For all of 
the confirmed target exons, the core and flanking motifs were separated by 14-29 nucleotides, 
and multiple branch site candidates were located between the CUGBP2 motifs (Figure 23). Note 
that exon 6 of the SCAMP3 transcript, which contains two mismatches to the GU-rich motif 
pattern, was insensitive to silencing by CUGBP2. MAPT_E2 is shown as a positive control 
because GRIN1 is not expressed in HEK293T cells (data not shown). Note that across all 
CUGBP2 target exons, it does not seem that the strength of the 5´ and 3´ splice sites as 
determined by ESEfinder 3.0 (Cartegni et al., 2003; Smith et al., 2006) influences CUGBP2 
regulation, providing support for CUGBP2 acting independently of exon definition events (Table 
3). Furthermore, the size of the exon does not appear to influence the ability of CUGBP2 to 
function as a splicing silencer. Taken together, these data suggest that branch site inhibition 
from flanking interaction motifs is a general mechanism for CUGBP2 splicing silencing and that 
CUGBP2 does not act on a subset of alternatively spliced exons. 
An interesting observation was the appearance of an exon skipped product of the 
CUGBP2 transcript itself, which was specific for conditions in which CUGBP2 was 
overexpressed (Figure 24A, CUGBP2_E6). However, the primers in this case also amplified 
mRNA expressed from transfected CUGBP2, thereby complicating interpretation. For this 
reason, I designed a downstream primer specific for the junction between exons 5 and 7, since 
such a junction primer should amplify only the skipped product from the endogenous mRNA. 
The junction primer was used together with a forward primer specific for the first exon. The 
results with this primer set clearly showed the accumulation of the exon 6 skipped version of the 
endogenous CUGBP2 transcript upon overexpression of CUGBP2 (Figure 24B, black box). 
Note that this primer set (E1/jxn) did not amplify the CUGBP2 protein expression vector or 
mRNA from transfected CUGBP2 (right). It is also important to note that although CUGBP2 
protein is not detected by Western blotting, there are low levels of CUGBP2 RNA in HEK293T 
cells. This may indicate that trace amounts of the protein are present in these cells or that the 
 105 
mRNA is translationally repressed. Furthermore, because there is an enrichment of CUGBP2 
protein in the rat cerebral cortex and a deficiency in the cerebellum (Zhang et al., 2002), I 
predicted and confirmed that there would be more skipping of exon 6 in the cortex (Figure 25). 
To establish the identity of the exon 6 skipped product, I cut the band out of the gel, cloned and 
sequenced it. The cloned product exactly matched the exon 5-7 junction sequence 
demonstrating its identity as the skipped product.  
 
Table 3. Summary of target exon size and strength. 
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 Figure 25. CUGBP2 exon 6 is skipped in the cerebral cortex but not the cerebellum. RT-
PCR of RNA from cerebral cortex (CC) and cerebellum (CE) of postnatal day 28 rat shows the 
E6 skipped mRNA in CC (lanes CUGBP2); white box, E6 skipped product cloned for sequence 
confirmation. Tissue-specific NMDA R1 receptor splicing patterns are shown as controls (lanes 
NI and CI). Lane L, 100 bp ladder. Brackets indicate sequence confirmed region of E5/E7 
junction. PTC, premature termination codon introduced into the reading frame as a result of E6 
skipping. 
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I also tested an exon in the CUGBP1 transcript that is homologous to CUGBP2 exon 6 
(Figure 23, CUGBP1_E6). Here, there is one mismatch to the core motif and although CUGBP2 
can silence this exon, the effect is less than other target exons with perfect matches to the 
consensus motifs (Figure 24, CUGBP1_E6 and Table 3). This suggests that CUGBP2 
regulation can be titrated depending on the sequence content and binding affinity to target 
motifs. 
4.3 AUTOREGULATION BY CUGBP2 
To determine whether CUGBP2 silences its own exon by a mechanism similar to that shown for 
the NI exon, exon 6 and the adjacent introns of CUGBP2 pre-mRNA were cloned into the DUP 
splicing reporter (Figure 26A). In this context overexpression of CUGBP2 had a robust silencing 
effect changing the exon 6 splicing pattern from 100% to 18% inclusion in transfected HEK293T 
cells (Figure 26B, lanes Wild type). To address the functional significance of the CUGBP2 
binding sites at the boundaries of the predicted branch sites, I tested site-directed mutations in 
the core (CORE) and downstream (DSM) motifs (Figure 26A). One perfect match to the branch 
site consensus (A2) and two additional candidates with a single mismatch (A1,A3) are the only 
plausible branch sites located within 100 nucleotides of the 3´ splice site of exon 6. Mutations in 
the CORE and DSM motifs resulted in a reduction of splicing silencing by CUGBP2 (Figure 26B, 
lanes CORE mt, DSM mt), and these effects were additive in the double mutant (lanes 
CORE/DSM mt). These are similar to the results shown for the NI exon providing additional 
support for the perimeter-binding model. Note that, although mutations did not completely 
eliminate CUGBP2 regulation of exon 6, footprinting experiments documented additional contact 
points extending from the CORE and DSM motifs suggesting that alternate binding registers  
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 Figure 26. CUGBP2 is autoregulated by silencing from exon 6 branch site perimeters. (A) 
DUP-CUGBP2 splicing reporter with sequence showing predicted branch sites (A1, A2, A3) and 
CUGBP2 binding motifs as detected by RNA footprinting in (D) (shaded regions). Primers 
(arrows) used for RT-PCR (βE1 and βE2) or footprinting analysis (E6) are shown. Mutations in 
core (CORE) and downstream (DSM) motifs are indicated (underscores). (B) Autoregulation of 
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E6 depends upon CUGBP2 binding motifs surrounding the branch site region. Gel panels 
represent RT-PCR analysis of wild type or mutant derivatives of the splicing reporter co-
expressed with vector backbone control (lanes vbb) or CUGBP2 protein expression vector 
(lanes CUGBP2) in HEK293T cells and are representative of three separate experiments. 
Percent exon inclusion values are shown below gel panels. (C) Footprinting analysis of the 
predicted branch site region upstream of E6 of CUGBP2 pre-mRNA. Starting material (lane 
SM), or RNA treated with CMCT in the absence (lane 0) or presence (lanes 3.6, 7.2, 14.4 µM) of 
CUGBP2 protein is indicated. Protected regions are indicated as shaded boxes at right with 
extended regions of protection (ext) from the CORE or DSM motifs indicated by arrows. 
Protected regions correspond to shaded nucleotides in (A). (D) Log difference of the band 
intensities of modified nucleotides in the absence or presence of 14.4 µM CUGBP2. Negative 
values represent regions protected by CUGBP2. Note that the strength of protection decreases 
with increasing distance from the primer used for primer extension. 
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might allow for some residual silencing (see below). Also note that I tested the possible role of 
an intronic UGUGU motif located 70 nucleotides downstream from exon 6. Mutation of this motif 
to UAUAU had a negligible effect on splicing silencing by CUGBP2, ruling out effects across the 
exon and further supporting our model (data not shown). Furthermore, I show that CUGBP1 can 
also regulate this exon but has a weaker silencing role compared to CUGBP2 in this context, 
and does not act through the CORE and DSM motifs like CUGBP2 (Figure 27).  
Finally, I used RNA footprinting to identify CUGBP2 contact sites in the neighborhood of 
the predicted branch sites upstream of exon 6 (Figure 26C/D). GU-rich motifs flanking A1, A2, 
and A3 were protected by the addition of purified CUGBP2 similar to that observed above for 
the NI 3´ splice site (Figure 26C, last three lanes at right). That is, two protected regions at the 
borders of the predicted branch sites overlap with the UGUGU core and UG flanking motifs in 
agreement with the perimeter-binding model. A difference in the pattern of protection, however, 
was the finding that two sets of motifs on either side of the branch site region extend outward 
indicating variations in the mode of binding compared to the NI exon. 
4.4 DISCUSSION 
Here, I have identified a combinatorial code that can be used to accurately predict CUGBP2 
target exons. This study underscores the importance of understanding direct nucleotide contact 
sites and the significance of a functional reference point in the prediction of splicing factor target 
exons. This code will be useful in the characterization of additional alternatively spliced exons. 
Furthermore, insights from this study can be applied to systematically examine the role of 
intronic mutations in the neighborhood of the branch site underlying mechanisms of human 
disease. The identification of an autoregulated exon in the CUGBP2 transcript and the finding 
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 Figure 27. CUGBP2 autoregulatory motifs are specific. Splicing reporters (top) were 
transfected into C2C12 cells in the presence (+) or absence (-) of CUGBP1 as indicated and 
included and skipped forms of spliced reporter RNA were assayed by RT-PCR and separated 
on a polyacrylamide gel. Percent exon inclusion (EI (%)) and the change in percent exon 
inclusion (ΔEI (%)) with CUGBP1 overexpression is indicated below the gel panel. ≠The effect of 
CUGBP2 overexpression is shown for comparison. 
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that the CUGBP1 and Fox2 splicing factors are cross-regulated by CUGBP2, implicates 
CUGBP2 in a network of splicing factor regulation. This network could have a general impact on 
the fine-tuning of splicing patterns in a brain region- and developmental- specific manner. 
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5.0   DISCUSSION 
An in depth analysis of the silencing face of the CUGBP2 splicing factor has revealed the 
functional nucleotide contacts involved in high affinity binding by CUGBP2, a novel mechanism 
for splicing silencing, and a combinatorial code for CUGBP2 regulation. This study has provided 
insight into global regulation by this splicing factor and has revealed a role for CUGBP2 in its 
own autoregulation and cross-regulation of family members. Furthermore, analysis of CUGBP2 
mutant proteins has demonstrated that multiple RRMs facilitate multiple recognition events at 
flanking GU-rich contact sites for high affinity binding. Results from these studies provide a 
starting point to study the role of CUGBP2 in the regulation of additional target exons and to 
examine the enhancing face in more detail. 
5.1 A COMBINATORIAL CODE FOR SPLICING SILENCING BY CUGBP2 
In this study, I identified a combinatorial code that can be used to predict exon silencing by the 
CUGBP2 alternative splicing factor. I initially used the NI cassette exon of the NMDA receptor 
NR1 subunit as a model exon to study RNA recognition by this factor. The first hint of how this 
exon target is recognized was revealed by chemical modification RNA footprinting of a high 
affinity binding region, which showed two contact sites – a core UGUGU and flanking GU – 
closely positioned in the neighborhood of the branch sites upstream from the NI exon (Figure 6). 
These contact sites and a third weaker footprinting site were shown to modulate alternative 
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splicing of the NI exon in vivo (Figure 10). I further demonstrate that transfer of these motifs is 
sufficient to confer CUGBP2 splicing silencing to an unregulated exon (Figure 13). Furthermore, 
I use this motif code to predict and identify additional CUGBP2 target exons with an accuracy of 
91% (10 out of 11 testable exons were regulated), satisfying the criteria for a splicing code as 
indicated in Chapter 1. I provide additional support for this code by identifying a similar 
arrangement of functional motifs in the intron upstream from the autoregulated exon 6 of the 
CUGBP2 transcript (Figure 26). That a set of motifs flanking a functional reference point can be 
used in combination to predict regulation by a splicing factor with high accuracy is a novel 
finding of this study and has general implications for refining computer programs with predictive 
value. 
Our results support and extend those of a previous study, which reported the 
identification of a UGUGUU motif as an intronic splicing regulatory element (U17) enriched 
within 400 nucleotides upstream of conserved skipped exons (Yeo et al., 2007). This previous 
study reported the association of the U17 element with exon inclusion in brain tissue as 
indicated by microarray analysis. In contrast, this study shows that the UGUGU core of the U17 
element is generally associated with exon silencing when the motif is paired with a flanking GU 
surrounding the functional branch sites. This is not necessarily a discrepancy, but more likely a 
reflection of a mechanism operating on a subset of exons containing a U17-related element. 
This observation provides support for the value of the branch site as a functional reference point 
that can be used together with the precise binding interaction motifs of a splicing factor to 
computationally predict new splicing regulatory targets.  
Our results are consistent with the types of binding motifs identified for CUGBP2 using a 
SELEX approach, although the relationship of the binding motifs to the branch site region and 
the autoregulatory role of CUGBP2 were not determined (Faustino and Cooper, 2005). 
Furthermore, the types of motifs identified for CELF proteins on the α-actinin transcript are in 
agreement with our results (Suzuki et al., 2002). In this study, the authors demonstrated that 
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CUGBP2 can bind to a short RNA containing a set of GU-rich motifs but not to a similar RNA 
containing one GU-rich stretch. Additionally, the GU-rich silencing motifs studied were located 
upstream of the regulated exon positioned on either side of the branch site. Note that the 
authors did not comment on either of these observations. In further support of our splicing code, 
insulin receptor exon 11 and MAPT exon 2 contain a similar arrangement of motifs flanking the 
branch site region in their upstream introns. GU- and U-rich stretches are also located in the 
vicinity of the branch site of the aberrantly retained intron of ClC-1 pre-mRNA. Taken together, 
these observations support the generality of the splicing code for CUGBP2 regulation although 
the functional significance of these motifs has not been determined.  
The splicing code described here provides an explanation for how splicing factors can 
achieve high specificity given the short and degenerate nature of their cognate RNA binding 
sites. The use of multiple binding motifs separated by variable space increases the specificity of 
recognition. Furthermore, the use of the branch site as a functional reference point further 
increases the specificity of the code. However, it is not known if recognition is mediated by the 
branch site or by factors interacting at the branch site. The footprinting assay used in this study 
is limited in that interactions with unmodified nucleotides and loose interactions that allow the 
chemical to enter the RNA-protein complex would be missed. In the future, we could further 
refine the code for CUGBP2 regulation by determining the limits in spacing between the GU-rich 
motifs. At present, it seems that a 12-30 nucleotide space is tolerated, although lower and 
higher limits have not been tested. Furthermore, we could determine if there is flexibility in the 
sequence content of motifs. For example, can CUGBP2 recognize a UCUGU core motif or 
flanking CU? These details will collectively help to refine the code for CUGBP2 splicing 
silencing. 
Microarray analysis comparing wild type primary cortical cultures to those without 
CUGBP2 would be an alternate approach to identify a complete list of target exons that are 
either silenced or enhanced by CUGBP2. Analysis of CUGBP2 recognition motifs in target 
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exons could be used to further refine the code for CUGBP2 regulation. Results from these 
studies would also be helpful in generating a map of the positional significance of target motifs 
for either enhancement or silencing by CUGBP2 as was done for Nova splicing factors (Ule et 
al., 2006). However, such studies are limited because we have not been able to generate a 
CUGBP2 knock out mouse and lentiviral approaches for shRNA-mediated knock down of 
CUGBP2 in primary cortical cultures have been unsuccessful so far. Tissue-specific expression 
of CUGBP2 makes it difficult to carryout siRNA in cell lines and conventional RNAi by 
transfection of siRNAs into primary cortical cultures is not possible because of very low 
transfection efficiencies (approximately 10% of neurons are transfected by lipofectamine or 
calcium phosphate transfection methods). Therefore, the best method currently available to 
study the effects of CUGBP2 on alternative exons is by overexpression in cell lines lacking 
endogenous CUGBP2. Still, analysis can be hindered by minimized silencing effects because of 
endogenous CUGBP1 acting on a subset of target exons or by the lack of expression of many 
neural-specific transcripts in cell lines tested. Furthermore, cross-regulation of Fox2, CUGBP1, 
and possibly other splicing factors by CUGBP2 complicates interpretation of overexpression and 
even RNAi approaches. This cross-regulatory effect probably explains why overexpression of 
CUGBP2 in N18TG2 cells causes an increase in NI exon inclusion when all three GU-rich motifs 
are mutated (Figure 10C, lanes m1,2,3). Therefore, it is best to use a combination of 
experimental approaches to study splicing regulation as was done in this study. 
5.2 SPLICING SILENCING BY BRANCHPOINT INHIBITION 
In this study, I focused on the silencing face of the dual functional splicing factor, CUGBP2, to 
understand how it silences the NI exon. Here, the positions of the branch sites were mapped 
between the core and flanking CUGBP2 target motifs (Figure 15). These branch sites were 
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collectively inhibited by CUGBP2 with a dependence on the presence of flanking GU-rich 
binding sites. Thus, guilt-by-association places CUGBP2 at the boundaries of the branch sites it 
regulates in support of the three-motif occupancy model illustrated in Figure 15A. Furthermore, I 
clearly demonstrate that CUGBP2 inhibits branchpoint formation by blocking U2 snRNP 
association (Figure 20) but has no effect on exon definition events (Figures 20, 21, and 22), in 
support of the silencing model illustrated in Figure 28. The regulation of an ensemble of 
branchpoints by a perimeter-type binding model, and the discovery that an exon in the CUGBP2 
transcript is itself silenced by a similar arrangement of binding motifs, are novel findings of this 
study. 
Branchpoint formation reflects a critical step in the catalysis of the splicing reaction, but 
its role in the regulation of alternative splicing across the transcriptome represents largely 
uncharted territory. Only a small number of branchpoints have been experimentally mapped, 
however, and there are often multiple candidate branch sites in the 3´ splice site region that 
match the consensus sequence (Gao et al., 2008). Examples of alternative splicing regulation 
through the use of a suboptimal branchpoint include the calcitonin/calcitonin gene-related 
peptide exon 4 and fibroblast growth factor receptor 2 exon IIIc (Emeson et al., 1989; Adema 
and Baas, 1991; Zandberg et al., 1995; Hovhannisyan and Carstens, 2005). Branch site 
selection has also been implicated in the regulation of mutually exclusive exons of beta 
tropomyosin and in the processing of human growth hormone pre-mRNA (Hartmuth and Barta, 
1988; Helfman and Ricci, 1989).  
What advantages would a perimeter-binding model provide for the control of access to 
the branch site region? The pre-mRNA branch site and flanking sequences are sequentially 
contacted by several factors during spliceosome assembly (Staknis and Reed, 1994b; Chiara et 
al., 1996). The branch site interacts with the RS domain of U2AF65 bound to the polypyrimidine-
tract of the 3´ splice site, followed by interactions with the RS domain of an SR splicing factor  
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 Figure 28. Model for splicing silencing by CUGBP2. (A) U1 snRNP, U2AF, and SF1 bind to 
the 5´ and 3´ splice sites and branch site sequence for effective complex E formation on the NI 
substrate containing the exon (rectangle) and flanking introns (lines) to define the exons to be 
spliced. (B) CUGBP2 at the perimeters of the branch site inhibits ATP-dependent U2 snRNP 
association and complex A formation. U2 snRNP can effectively replace SF1 at the downstream 
branch site to position the branchpoint adenosine for nucleophilic attack. (C) Two ATP-
dependent transesterification reactions and several spliceosomal rearrangements (not shown) 
occur.  (D) The upstream and downstream exons are joined and the lariat intron containing the 
upstream intron, NI exon, and downstream intron is removed. 
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bound to an enhancer element in the adjacent exon (Valcarcel et al., 1996; Shen and Green, 
2004; Shen et al., 2004). SF1 makes direct contacts with the branch site during complex E 
assembly (Abovich and Rosbash, 1997; Liu et al., 2001). In complex A, SAP155 binds to sites 
flanking the branch site and replaces SF1 to recruit U2 snRNP (Berglund et al., 1998; Gozani et 
al., 1998). Here multiple contact sites furnish CUGBP2 with the stability to inhibit the association 
of U2 snRNP with the branch site region to block conformational transitions of the spliceosome. 
By binding to the perimeters of the branch site, CUGBP2 may allow for SF1 association during 
complex E but block access of the U2 snRNP-associated SAP155. Moreover, a recent study 
has demonstrated that CUGBP2 can physically interact with SF3b of the U2 snRNP and RNA 
helicases DDX1 and DHX9 among other proteins (Goo and Cooper, 2009). Therefore, CUGBP2 
may in part function to recruit a helicase to the U2 snRNP-pre-mRNA duplex to disrupt base 
pairing if complex A has already formed. However, the spliceosome assembly assays used here 
are limited in that they cannot differentiate between these possibilities. The perimeter-type 
binding model described here is significant in allowing for the coordinate regulation of multiple 
branchpoints to control alternative splicing of a cassette exon. Furthermore, by binding in 
alternate registers around the branch site region, CUGBP2 may be able to inhibit association of 
other factors on different RNA substrates and therefore function by alternate mechanisms. 
Why would CUGBP2 inhibit complex A and not complex E, allowing the exon to be 
defined but not spliced? In this way, the splicing machinery could more quickly adjust to 
environmental cues, such as cell depolarization. Post-translational modification of CUGBP2 in 
response to environmental signals, for example, may adjust its binding and silencing ability. 
Quick removal of CUGBP2 from the pre-mRNA would allow access of U2 snRNP and assembly 
of complexes A, B, and C for catalysis of splicing. Inhibiting a step later than exon definition, 
therefore, may allow for faster adjustments in exon selection, which would be particularly useful 
in the nervous system where CUGBP2 is expressed. 
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5.3 MODULAR BINDING BY CUGBP2 FACILITATES HIGH AFFINITY AND SEQUENCE 
SPECIFICITY 
Here I demonstrate that multiple RRMs collaborate for high affinity binding and sequence 
recognition by CUGBP2. I show that RRMs 2 and 3 are sufficient for protection of flanking GU-
rich sequence elements in the footprinting assay (Figure 8). In support of this, RRM3 is 
necessary but RRM1 and the divergent domain are dispensable for high affinity binding by 
CUGBP2 (Table 2). It is likely that RRMs 2 and 3 bind to the upstream and core motifs, 
respectively, with the divergent domain allowing for flexibility in the spacing between motifs 
(Figure 9). In support of this, the ΔDD mutant binds to the same motifs as the wild type protein 
(Figure 8) but with half the affinity (Table 2). It is likely in this case that two proteins bind to the 
upstream and core motifs with less affinity than one protein binding to both of these motifs as for 
the wild type protein. That is, without the divergent domain to position RRMs 2 and 3 relative to 
each other, one protein cannot simultaneously contact distance sites. The finding that flanking 
interaction sites are necessary for high affinity binding and the suggestion that multiple RRMs 
cooperate to facilitate this binding are of interest to this study. 
CUGBP2 is a modular protein containing three RRMs in which a divergent domain of 
unknown function separates RRMs 2 and 3. The domain structure of the protein may be geared 
to facilitate binding of a monomer to a pair of core and flanking motifs forming a bridge between 
them as our model indicates (Figure 9). Alternatively, a single monomer might bind to all three 
GU-rich motifs. Both models would limit access to the branch sites by factors sliding along the 
RNA from upstream and downstream directions. Our footprinting results with CUGBP2 are in 
agreement with previous structural studies showing that a single RRM can contact ~2-7 
nucleotides of its bound RNA ligand (Figure 8) (Ding et al., 1999; Oberstrass et al., 2005; 
Sickmier et al., 2006). Given the inherent flexibility of RNA binding proteins, it would not be 
surprising that breathing motions of CUGBP2 could adjust the relative conformations of the 
 121 
RRM domains to optimize recognition specificity in different sequence contexts. Still, 
interpretation of RRM mutant studies is limited because charge differences in the linker region 
between RRMs 2 and 3 may alter binding characteristics. Furthermore, individual RRMs may 
act differently when taken out of the wild type context. In the future, structural studies will be 
required to completely understand the topology of binding associated with CUGBP2’s silencing 
function. 
5.4 AUTOREGULATION BY CUGBP2  
Here I reveal a novel autoregulatory role for CUGBP2. I demonstrate that overexpression of 
CUGBP2 causes an increase in exon 6 skipping in HEK293T cells (Figure 24). Furthermore, the 
exon 6 skipped product is detected in mRNA prepared from the rat cerebral cortex but not 
cerebellum, consistent with the brain region-specific expression of CUGBP2 (Figure 25). I verify 
that the exon 6 skipped product exactly matched the exon 5/7 junction and was not a non-
specific PCR band. Moreover, in the context of a cloned splicing reporter, CUGBP2 
overexpression caused increased skipping of exon 6, with a dependence on GU-rich motifs 
flanking the predicted branch sites (Figure 26). Finally, I demonstrate that CUGBP2 physically 
contacts GU- and U-rich motifs at the perimeters of the exon 6 branch sites, in support of the 
perimeter-binding model described for the NI exon.  
Autoregulation has been shown for a growing number of splicing factors, including PTB, 
Fox2, Nova1, SRp20, SC35, TIA1, and TIAR (Wollerton et al., 2004; Dredge et al., 2005; 
Baraniak et al., 2006; Ni et al., 2007). Here I dissect the mechanism of CUGBP2 autoregulation 
in great detail, making this one of the best-characterized examples of autoregulation. 
Conceptual translation reveals that skipping of exon 6 causes a shift in the reading frame, which 
introduces a PTC in the exon 7 region of the transcript. In this way, the resulting transcript could 
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be targeted for NMD. Conversely, translation of the exon 6 skipped transcript could generate a 
truncated protein ending within RRM2. The advantage of a tight motif arrangement around the 
branch site region would be to dynamically adjust exon 6 inclusion based on fluctuations in the 
levels of CUGBP2 protein.  
The observation that CUGBP2 can cross-regulate exons in the CUGBP1 and Fox2 
transcripts (Figure 24), and that CUGBP1 can silence CUGBP2 exon 6 to a lesser extent 
(Figure 27), implicates CUGBP2 in a network of splicing factor regulation. I speculate that this 
may be important in specifying neural cell identity and for fine-tuning of neural exon splicing. In 
the future, it would be of interest to study the differences in binding specificities and target exon 
selection by CUGBP1 and CUGBP2. 
5.5 FINE-TUNING OF SPLICING IN THE NERVOUS SYSTEM BY CUGBP2 
The binding of CUGBP2 to the perimeters of the branch sites allows for sensitive gradations 
specifying the levels of NI exon inclusion. Because the peptide region encoded by the NI exon 
modulates sensitivity of the NMDA receptor to zinc ions, protons, and polyamines, such a 
mechanism would be advantageous for fine-tuning this modular property of receptor function in 
different regions of the brain or during development (Lipscombe, 2005). The biochemical 
functions of NMDA receptors are of fundamental importance in synaptic plasticity where deficits 
in this subunit are associated with altered brain function in the context of Alzheimer’s disease. 
The CI cassette exon, which is regulated by the enhancing face of CUGBP2, encodes a 
functionally important region of the receptor involved in membrane trafficking and signaling to 
the nucleus. Additional CUGBP2 target exons function in processes such as alternative splicing 
(CUGBP2, CUGBP1, FOX2), transcription (NFAT5, MLLT10, SMARCE1, CTBP1), microtubule 
assembly (MAP4, MAPT), axon guidance (PPFIBP1), and insulin signaling (SORBS1, insulin 
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receptor). These processes have a general impact on neuronal function and fine-tuning of 
splicing of these and additional factors in the nervous system by CUGBP2 may be associated 
with specifying neural cell identity. 
5.6 INSIGHTS INTO THE MECHANISMS OF SPLICING ENHANCEMENT BY CUGBP2 
This study provides the starting point to investigate the broader roles of CUGBP2 in regulation 
of the CI cassette and additional exons throughout the transcriptome. How do RNA elements 
recognized by CUGBP2 for splicing enhancement differ from those recognized for splicing 
silencing? Are different nucleotides recognized for enhancement or are the positions of the 
motifs relative to the exon more important? Currently, cTNT exon 5 and the CI cassette are the 
only exons known to be enhanced by CUGBP2. In support of the positional significance of 
motifs for regulation, both of these exons contain GU-rich motifs in their downstream introns. 
Furthermore, several alternative splicing factors have been shown to bind near the 3´ splice site 
to silence an alternative exon and in the downstream intron for enhancement (Baraniak et al., 
2006; Ule et al., 2006). Therefore, mechanisms of dual regulation by CUGBP2 may be similar to 
those used by other splicing factors. 
I have footprinted CUGBP2 to a core UCUGU and downstream flanking UG dinucleotide 
in the intron downstream from the CI exon (data not shown). However, mutation of these sites 
only had a modest effect on splicing enhancement by CUGBP2. Therefore, downstream from 
the CI exon additional low affinity sites are likely involved in regulation. In fact, multiple GU-rich 
sequence elements are located near the 5´ splice site. In the future, it would be of interest to 
determine the effects of combinations of mutations to these GU-rich motifs for splicing 
enhancement by CUGBP2. Furthermore, what is the minimal sequence requirement for 
enhancement in a heterologous context? However, these studies are limited because CUGBP2 
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regulatory motifs may overlap with other control elements for alternative or constitutive splicing 
regulation. Additionally, if CUGBP2 functions to antagonize a splicing silencer, transfer assays 
would not be useful for understanding regulation. Still, a complete understanding of the 
sequence elements involved in splicing enhancement of the CI exon could provide insight into 
the mechanisms of dual regulation by CUGBP2 and other splicing factors. 
 A recent study has demonstrated that CUGBP2 can enhance inclusion of cTNT exon 5 
by binding to GU-rich elements near the 5´ splice site in the downstream intron to recruit U2 
snRNP to the branch site in the upstream intron (Goo and Cooper, 2009). This mechanism of 
enhancement is similar to that shown for SR proteins (reviewed by (Graveley, 2000)). 
Furthermore, CUGBP2 has also been shown to compete with PTB and MBNL splicing silencers 
for exon 5 enhancement (Ladd et al., 2005). It is likely that a combination of these effects are 
involved in splicing enhancement of cTNT exon 5 by CUGBP2.  
Potential models for splicing enhancement of the CI exon are illustrated in Figure 29. 
These include a cross exon definition model (A) and antisilencing model (C) as have been 
demonstrated for cTNT exon 5. Additionally, I suggest an alternate, intron definition model (B). 
The intron definition model predicts that CUGBP2 at the 5´ splice site interacts with components 
of the U2 snRNP at the downstream 3´ splice site to facilitate the transition from an exon 
defined spliceosome to a catalytically active intron defined spliceosome. In support of this 
model, CUGBP2 interacts with two known helicases (Goo and Cooper, 2009). Therefore, 
CUGBP2 may recruit a helicase to assist in structural rearrangements of the spliceosome for 
release of U4 snRNP. Although, these models for CI splicing enhancement are currently only 
speculative, they provide a good starting point to study the mechanisms of regulation by this 
factor. 
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 Figure 29. Models for splicing enhancement by CUGBP2. Exon Definition Model: CUGBP2 
binds to the intron downstream of the CI exon. Here it may facilitate protein-protein interactions 
with U2 snRNP across the CI exon to aid in exon definition. Intron Definition Model: Alternately, 
CUGBP2 may interact with U2 snRNP at the downstream 3´ splice site, across the large 
downstream intron (>1900 nucleotides), to assist in the transition from an exon-defined 
spliceosome to an intron-defined spliceosome. Antisilencing Model: CUGBP2 may function to 
antagonize a splicing silencer in the 5´ splice site region of the CI exon to facilitate exon 
inclusion. 
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5.7 FUTURE EXPERIMENTS 
Although this study has answered many questions about the specificity of binding and 
mechanism of splicing silencing by CUGBP2, it has raised even more questions. What is the 
positional significance of target motifs for silencing and enhancement? Does CUGBP2 
recognize variations in the GU-rich RNA elements for regulation of a subset of target exons? If 
so, does CUGBP2 bind with different affinity to different sequence elements to specify splicing 
regulation based on fluctuations in protein levels? What additional target exons are regulated by 
CUGBP2? Do these target exons share common characteristics and does splicing of these 
exons tune modular protein functions in the cerebral cortex?  What is the mechanism of splicing 
enhancement? Does CUGBP2 recruit factors associated with the general splicing machinery or 
compete with splicing silencers? What is the significance of the autoregulated splicing event? 
Does it serve as a feedback mechanism to regulate CUGBP2 protein levels? Moreover, how do 
binding differences of CUGBP1 and 2 direct target exon selection by these related family 
members? Answers to these questions will provide a more complete understanding of CUGBP2 
function and will also offer insight into global mechanisms of alternative splicing regulation. 
In the future, it would be of interested to refine the spicing code for CUGBP2 and use 
this information to generate a computer program to predict regulation by this factor. One way to 
do this would be to use splicing microarrays to compare splicing patterns in the presence and 
absence of endogenous CUGBP2 in the cerebral cortex. Target exons could be verified by RT-
PCR and cloned into splicing reporters to determine the significance of the regulatory motifs by 
site-directed mutagenesis. These assays would provide insight into the network of exons 
regulated by CUGBP2, would help to further refine the splicing code, and could be used to 
generate a map to predict enhancement or silencing based on the position of target motifs.  
Furthermore, structural studies could be used to completely understand the topology of 
binding by CUGBP2. In the past, such studies have been difficult because the inherent flexibility 
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of domains within the protein have made it difficult to crystallize. Additionally, attempts to 
crystallize individual RRMs and RRMs bound to an RNA ligand have been unsuccessful. 
Alternate approaches such as NMR or limited proteolysis may be more useful for structural 
analysis of this protein. 
It would be of interest to dissect the mechanism of enhancement of the CI exon by 
CUGBP2. Mutational analysis of GU-rich motifs downstream from the CI exon in an in vivo 
splicing reporter system could be used to identify functionally significant motifs and in vitro 
splicing assays could be used to determine the effect of CUGBP2 on spliceosome assembly. It 
would also be interesting to follow up on the observation that the ΔDD mutant (containing RRMs 
1, 2, and 3) has an enhancing effect on splicing of the NI exon while the RRM2_3 mutant 
(containing RRMs 2 and 3) has a silencing effect. Does RRM1 interact with proteins involved in 
splicing enhancement? Or do charge differences in the linker region between RRMs 2 and 3 of 
these two mutants account for this functional difference? 
Finally, it would be interesting to determine how splicing patterns regulated by CUGBP2 
are adjusted in response to cell depolarization. Is CUGBP2 modified in response to cell 
signaling or is this factor unresponsive to such events? Several potential phosphorylation sites 
are located in the divergent domain of CUGBP2. In the future, it would be interesting to 
determine whether these sites are used and how modification at these sites modulates protein 
activity. 
Taken together, I have provided insight into how splicing factors in general can 
recognize their cognate RNA substrates with high specificity by recognizing multiple contact 
sites on one pre-mRNA. Furthermore, I have characterized a novel mechanism of splicing 
silencing in great detail that is likely to be utilized by additional splicing silencers and dual 
functional regulators. This study also changes the way we think about splicing codes in that 
multiple recognition events and a functional reference point may be necessary to accurately 
predict splicing factor regulation of additional splicing factors. Moreover, cross-regulation and 
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autoregulation by splicing factors means that we need to be more careful about interpretation of 
results from overexpression and RNAi approaches in the future. Finally, the combination of 
approaches used in this study can be applied to characterize splicing codes and mechanisms of 
regulation by additional splicing factors that control alternative splicing events.  
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